Study Title: 
Sponsor: 
IND Number: 
Eudra CT N umber: (rJ GILEAU 
CLINIC AL STUDY PROTO COL 
A Phase 3b Open-Label Pilot Study to Evaluate Switching to 
Elvitegravir /Cobicistat/E mtricitabine/T en ofovir Alafe namide 
(E/C/F/TAF) Fixed Dose Comb ination (FDC) in 
Virolog ically-Su ppressed HIV-1 Infected Adult Subjects 
Harboring the Arc hived Isolated NRTI Resistance Mutation 
M184V/M184 I 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
111,007 
2015-0027 10-74 
Clinical Trials.gov Identifier: NCT026 16029 
Indication: 
Protocol ID: 
Gilead Clinical Program 
Manag er: 
Gilead Medical Monitor: 
Gilead Study Director: 
Protocol Version/Date: HIV-1 Infection 
GS-US-292-1824 
Name: 
Telep hone: 
Fax: 
Name: 
Telep hone: 
Mobile: 
Name: 
Telep hone: 
Mobile: 
Original : 
Ame ndment 1: PPD 
PPD 
PPD 
29 July2015 
19 August 2016 
CONFIDENTIALITY STAT EMEN T 
The info1mat ion contained in this docume nt, paiiic ularly unpublished data, is the prope 1iy or 
unde r control of Gilead Sciences, Inc., and is provide d to you in confidence as an investigato r, 
potential investigato r, or consultant, for review by you, your staff, and an applicable 
Institution al Review Boai·d or Independent Ethics Commi ttee. The infonnatio n is only to be used 
by you in connection with author ized clinical studies of the investigatio nal d rng described in the 
protocol. You will not disclose any of the info1matio n to others without writte n auth orizat ion 
from Gilead Sciences, Inc., except to the extent necessaiy to obtain info1med consent from those 
perso ns to whom the d rng may be admin istered. 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 2 19August 2016TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ........................................................................................................................................ 4
LIST OF IN-TEXT FIGURES ................................
...................................................................................................... 4
PROTOCOL SYNOPSIS .............................................................................................................................................. 5
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 11
1. INTRODUCTION .............................................................................................................................................. 15
1.1. Background ............................................................................................................................................ 15
1.2. Tenofovir Alafenamide (TAF, GS -7340) ............................................................................................... 17
1.2.1. General Information ............................................................................................................. 17
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 17
1.2.3. Clinical Trials of E/C/F/T AF............................................................................................... 19
1.3. Information About Comparator Regimens ............................................................................................. 21
1.4. Rationale for this Study .......................................................................................................................... 21
1.5. Risk/Benefit Assessment for the Study .................................................................................................. 21
1.6. Com pliance ............................................................................................................................................ 21
2. OBJECTIVES ................................
..................................................................................................................... 22
3. STUDY DESIGN ..............................................................................................................................
.................. 23
3.1. Study Design .......................................................................................................................................... 23
3.2. Study Treatments ................................................................................................................................... 24
3.3. Duration of Treatment ............................................................................................................................ 24
3.4. End of Study ........................................................................................................................................... 24
3.5. Post Study Care ...................................................................................................................................... 24
3.6. Source Data ............................................................................................................................................ 25
3.7. Samples for Optional Exploratory Assessments .................................................................................... 25
4. SUBJECT POPULATION .................................................................................................................................. 26
4.1. Number of Subjects and Subject Selection ............................................................................................ 26
4.2. Inclusion Criteria ..............................................................................................................................
......26
4.3. Exclusion Criteria ................................................................................................................................... 28
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 30
5.1. Enrollment .............................................................................................................................................. 30
5.2. Description and Handling of E/C/F/TAF FDC ...................................................................................... 30
5.2.1. Form ulation .......................................................................................................................... 30
5.2.2. Packaging and Labeling ....................................................................................................... 30
5.2.3 . Storage and Handling ........................................................................................................... 31
5.3. Dosage and Administration of E/C/F/TAF FDC .................................................................................... 31
5.4. Prior and Concomitant Medications ....................................................................................................... 31
5.5. Accountability of Study Drug ................................................................................................................ 36
5.5.1. Study Drug Return or Disposal ................................
............................................................ 36
6. STUDY PROCEDURES .................................................................................................................................... 37
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 37
6.2. Pretreatment Assessments ...................................................................................................................... 37
6.2.1. Screening Visit ..................................................................................................................... 37
6.2.2. Day 1 Visit ........................................................................................................................... 39
6.3. Treatment Assessments .......................................................................................................................... 40
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 3 19August 20166.3.1. Treatment Visits (Weeks 4 –48).......................................................................................... 40
6.4. Post-treatment Assessments ................................................................................................................... 43
6.4.1. Early Study Drug Discontinuation (ESDD) Visit ................................................................. 43
6.4.2. 30-Day Follow -up Visit ............................................................... ......................................... 44
6.5. Assessments for Premature Discontinuation from Study ....................................................................... 45
6.6. Criteria for Discontinuation of Study Treatment .................................................................................... 45
6.7. Other Evaluations ................................................................................................................................... 46
6.7.1. Blood and Urine Storage ...................................................................................................... 46
6.8. Virologic Failure .................................................................................................................................... 46
6.8.1. Management of Virologic Failure ........................................................................................ 46
6.8.2. Resistance Analys is at Subjects Last Visit ........................................................................... 47
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 49
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 49
7.1.1. Adverse Events ..................................................................................................................... 49
7.1.2. Serious Adverse Events ........................................................................................................ 49
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 50
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................
.50
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 50
7.2.2. Assessment of Severity ........................................................................................................ 51
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ................................................................
....................................................... 51
7.4. Gilead Reporting Requirements ............................................................................................................. 53
7.5. Toxicity Management ............................................................................................................................ 53
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 54
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event ............................................................. 54
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event ............................................................. 54
7.5.4. Management of Potential Nephrotoxicity ............................................................................. 54
7.6. Special Situations Reports ...................................................................................................................... 55
7.6.1. Definitions of Special Situations .......................................................................................... 55
7.6.2. Instructions for Reporting Special Situations ....................................................................... 56
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 58
8.1. Analysis Objectives and Endpoints ........................................................................................................ 58
8.1.1. Analysis Objectives .............................................................................................................. 58
8.1.2. Primary Endpoint ................................................................................................................. 58
8.1.3. Secondary Endpoint ............................................................................................................. 58
8.2. Analysis Conventions ............................................................................................................................. 59
8.2.1. Analysis Sets ........................................................................................................................ 59
8.3. Dem ographic Data and Baseline Characteristics ................................................................................... 59
8.4. Efficacy Analysis ................................................................................................................................... 59
8.4.1. Primary Analysis .................................................................................................................. 59
8.4.2. Secondary Analyses ............................................................................................................. 60
8.5. Safety Analysis ..............................................................................................................................
......... 60
8.5.1. Extent of Exposure ............................................................................................................... 60
8.5.2. Adverse Events ..................................................................................................................... 60
8.5.3. Laboratory Evaluations ........................................................................................................ 61
8.5.4. Other Safety Evaluations ...................................................................................................... 61
8.6. Sample Size ..............................................................................................................................
.............. 61
8.7. Data Monitor ing Committee .................................................................................................................. 61
9. RESPONSIBILITIES .......................................................................................................................................... 62
9.1. Investigator Responsibilities ...............................................................
................................................... 62
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 4 19August 20169.1.1. Good Clinical Practice .......................................................................................................... 62
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... 62
9.1.3. Informed Consent ................................................................................................................. 63
9.1.4. Confidentiality ...................................................................................................................... 63
9.1.5. Study Files and Retention of Records .................................................................................. 63
9.1.6. Case Report Forms ............................................................................................................... 65
9.1.7. Inspections ............................................................................................................................ 65
9.1.8. Protocol Compliance ................................
............................................................................ 65
9.2. Spons or Responsibilities ........................................................................................................................ 65
9.2.1. Protocol Modifications ......................................................................................................... 65
9.2.2. Study Report and Publications ............................................................................................. 65
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 66
9.3.1. Payment Reporting ............................................................................................................... 66
9.3.2. Access to Information for Monitoring .................................................................................. 66
9.3.3. Access to Information for Auditing or Inspections .............................................................. 66
9.3.4. Study Discontinuation .......................................................................................................... 67
10. REFERENCES ................................................................................................................................................... 68
11. APPENDICES .................................................................................................................................................... 71
Appendix 1. Investigator Signature Page .................................................................................................... 72
Appendix 2. Study Procedures Table .......................................................................................................... 73
Appendix 3. Management of Clinical and Laboratory Adverse Events ...................................................... 75
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 76
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 98
Appendix 6. AIDS -Defining Condit ions (CDC Guidelines) {Selik et al 2014} ....................................... 101
LIST OF IN -TEXT TABLES
Table 3-1. Part 1 and Part 2 Resistance Criteria ...................................................................................... 23
Table 4-1. Allowable Third Antiretroviral Agents of Pre -Existing Regimen .......................................... 28
Table 4-2. Disallowed Agents ................................................................................................................. 29
Table 5-1. Prior and Concomitant Medications ....................................................................................... 32
LIST OF IN -TEXT FIGURES
Figure 3-1. Study Schema ......................................................................................................................... 24
Figure 6-1. Management of Virologic Failure .......................................................................................... 48
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 5 19August 2016PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lake side Drive
Foster City, CA 94404
Study Title : A Phase 3b O pen-Label Pilot Study to Evaluate Switching to 
Elvitegravir/ Cobicistat/ Emtricitabine/T enofovir A lafenamide 
(E/C/F/TAF) Fixed Dose Combination (FDC) in 
Virologically -Suppressed HIV -1 Infected A dult Subjects H arboring 
the A rchived Isolated N RTI Resistance Mutation M184V/ M184I
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:111,007
2015 -002710-74
TBD
Study Centers Planned: Approximately  38centers in Europe and North America
Objectives: The primary  objective of this study  is as follows:
To evaluate the efficacy  of E/C/F/TAF fixed dose combination 
(FDC) after switching from a stable regimen consisting of
FTC/TDF or ABC/3TC plus a third antiretroviral agent in 
maintaining HIV -1 RNA <50 copies/mL at Week 12
(using pure 
virologic response ) in subjects harboring the archived NRTI 
resistance mutation M184V and/or M184I in HIV -1 reverse 
transcriptase
The secondary  objectives of this study  are as follows:
To determine the safet y and tolerability of E/C/F/ TAF FDC in 
subjects switching from 2 NRTI plus third antiretroviral agent 
regimens
To evaluate the development of new resistance mutations in 
subjects who develop virologic failure after switching to 
E/C/F/TAF FDC
To determine the durability  of efficacy  at Weeks 24 and 48 in 
maintaining HIV -1 RNA <50 copies/mL using 
pure virologic response (PVR)
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 6 19August 2016Study Design: Open -label, single arm, multicenter study  to evaluate the efficacy  
and safet y of switching to E/C/F/TAF FDC in HIV -1 infected adult 
subjects with HIV -1RNA <50 copies/mL harboring an archived 
isolated M184V and/or M184I  mutation associated with NRTI 
resistance and who have been on a stable regimen consisting of 
FTC/TDF or ABC/3TC plus a third antiretroviral agent with HIV -1 
RNA below the detection limit for ≥ 6month s at screening. 
Subjects will have no evidence of previous virologic failure on a 
PI/r or INSTI -based regimen (with or without resistance to either 
class of ARV). Subjects may  have evidence of a prior virologic 
failure on an NNRTI plus 2 NRTI -based regimen. Prior treatment 
changes due to tolerability will be allowed as long as virologic 
failure was not the reason for treatment change and the subject 
remained continuousl y suppressed .
Part 1
In Part 1, the enrollment criteria will allow 50 subjects to enter the 
study  if they  have M184V and/or M184I in HIV- 1 reverse 
transcriptase WI THOUT any other NRTI resistance mutation 
(including th ymidine analogue -associated mutations (TAMs) 
[M41L , D67N, K70R, L210W, T215Y/F, and K219Q/E/N/R ], 
K65R, K70E, T69 ins ertion and Q151M mutation complex 
[A62V, V75I , F77L, F116Y, Q151M] ).
After these subjects in Part 1 have undergone their Week 12 visit, 
an interim efficacy  review will be done by  an internal Data 
Monitoring Committee (Internal DMC) that is independent of t he 
study  team and the study  conduct activities, to ensure the rate of 
virologic failure is not unacceptabl y high. A pure virologic 
response (PVR) of <80% would be considered unacceptable; 
safet ymonitoring will be designed to assure that the true value o f 
PVR is above 80%.
Part 2
If the rate of virologic failure in Part 1 is deemed acceptable, once 
the internal DMC officially  completes the interim review, entry  
criteria will be expanded and the study  will continue to Part 2.
In Part 2, the enrollment crit eria will be expanded to allow 
50additional subjects to enter the stud y if they have M184V and/or 
M184I  in HIV -1 reverse transcriptase WITHor WITHOUT
1 or 2 TAMs that include M41L , D67N, K70R, L210W, T215Y/F,
and K219Q/E/N/R (notincluding the K65R, K70E , T69 insertion, 
and/or Q151M mutation complex [A62V, V75I , F77L , F116Y, 
Q151M]).
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 7 19August 2016Safety  Monitoring of Virologic Failures
All HIV -1RNA values w ill be reviewed on an ongoing basis. 
Any post-Day 1HIV-1RNA ≥50 copies/mL  will be repeated 
within 2 -4weeks. Subjects with confirmed HI V-1RNA 
≥ 50 copies/mL  will be manage d indiscuss ionwith the Medical 
Monitor in accordance with guidelines developed for the 
E/C/F/TAF phase 3 program
.
Number of Subjects 
Planned:Approximately  100 subjects will be enrolled into the study .
Target Population: HIV
-1 infected adult s (≥ 18 years) with HIV -1 RNA < 50copies/mL 
on a stable regimen containing FTC/TDF or ABC/3TC plus a n 
(allowed) third antiretroviral agent (refer to Table 4-1) for 
≥
6consecutive months prior to screening and documented 
presence of NRTI resistance mutation M184V and/or M184I  in 
HIV
-1 reverse transcriptase .
Duration of Treatment: A 42 dayscreening period followed by 48 weeks of treatment and a 
30 Day  Follow -Upvisit after completion of stud y drug. 
Subjects that develop virologic failure will be followed for the 
duration of the study  or longer to document virologic suppression 
on a revised regimen.
Diagnosis and Main 
Eligibility  Criteria:HIV
-1 infect ed adult subjects w ho meet the following criteria will 
be given the option to participate in the study :
Documented plasma HIV -1 RNA levels < 50 copies/mL  for 
≥ 6months preceding and at the screening visit (measured at 
least twice using the same assay ). One unconfirmed virologic 
elevation or “blip” of ≥ 50 copies/mL  after previously  reaching 
viral suppression is acceptable.
Current ly receiving an antiretroviral ( ARV )regimen consisting 
of FTC/TDF or ABC/3TC plus a third antiretroviral agent for 
≥ 6consecutive months preceding the Screening visit . Refer to 
Table 4-1for allowed third agents .
No previous use of an y approved or experimental integrase 
strand transfer inhibitor (INSTI) (for an y length of time) if the 
current regimen contains a PI /r.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 8 19August 2016All subjects must have a historical genoty pe report showing 
M184V and/ or M184I (mixtures are acceptable) in HI V - 1 reverse 
transcriptase WI THOUT (Part 1) and WITH or WITHOUT (Part 2)
1 or 2 TAMs. Subjects must not have an y primar y INST I or 
primary  PI resistance mutations. A dditional NRTI resistance 
mutations not defined below are allowed, and NNRTI  mutations are 
allowed (see Table 3-1).
Subjects identified as having the indicated resistance mutation profile 
from a historical genot ype will then be teste d for archived resistance 
by proviral genoty pe analy sis (from whole blood) at screening visit. 
Proviral DNA tested must not have additional exclusion resistance 
mutations (defined in Table 3-1for Part 1or Part 2); if identified ,
subjects will be excl uded from entry  into the study.
Part 1 Resistance Criteria (first 50 subjects
): 
M184V and/orM184I (mixtures are acceptable) in reverse 
transcriptase WI THOUT any other NRTI resistance 
mutation (including TAMs [M41L , D67N, K70R, L 210W, 
T215Y/F, and K219Q/E/N/R ], K65R, K70E, T69insertion
and Q151M mutation complex [A62V, V75I , F77L, F116Y, 
Q151M] ).
Part 2 Resistance Criteria ( second 50 subjects; 
after theinterim efficacy review): M184V and/or M184I 
(mixtures are acceptable) in reverse transcriptase WITHor 
WITHOUT 1 or 2 TAMs [M41L , D67N, K70R, L210W, 
T215Y/F, and K219Q/E/N/R]. Evidence of K65R, K70E,
T69 insertion and/or Q151M mutation complex [A62V, 
V75I, F77L, F116Y, Q151M] in addition to the resistance 
mutations above will not be eligible for entry  into the study .
Must not have integrase or protease inhibitor ( PI)mutations present 
on historical genoty pe. Non-Nucleoside Reverse Transcriptase 
Inhibitor (NNRTI ) mutations are allowed.
Estimated glom erular filtration rate ≥ 30 mL/min according to the 
Cockcrof t-Gault formula for creatinine clearance
Study  Procedures/
Frequency :Following Screening, eligible subjects will be required to return for 
study  visits at Day  1, Weeks 4, 8, 12, 16, 24, 36 and 48.After the 
Week 48 visit, subjects will stop study  drug and complete a 30 -Day 
Follow -up visit to complete their participation in the study .
Laboratory  anal yses (hematology , chemistry , and urinaly sis), 
HIV
-1 RNA, CD4+ cell count, and complete or sy mptom directed 
physical examinations will be performed at Screening, Day 1and 
specific subsequent study visits. 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 9 19August 2016A whole blood sample will be collected at the Screening visit for 
proviral genot ype anal ysis for a rchived resistance in subjects that 
possess an eligible historical genot ype report. Subjects that develop 
virologic failure will have HIV -1 plasma genot ype/phenoty pe of 
reverse transcriptase, protease and integrase.
Test Product, Dose, and 
Mode of Administration:All subjects will receive elvitegravir 150 mg/cobicistat 150 mg/
emtricitabine 200 mg/ tenofovir alafenamide 10 mg (E/C/F/TAF) 
FDC , administered orally, once dail y, with food
Reference Therapy, 
Dose, and Mode of 
Administration:None
Criteria for Evaluation: Efficacy  of switch from the current regimen to E/C/F/TAF FDC 
will be evaluated using HIV -1 RNA values; safet y will be assessed 
with adverse events and clinical laboratory  tests.
Safety : Safety  of E/C/F/TAF FDC will be reviewed at Weeks 12, 24 and 48 
by assessing clinical laboratory  tests and adverse events during the 
study .
Health Related 
Questionnaires:Health related questionnaires will be administered, including the 
EQ-5D, Medical Outcome Study  Short Form -36 (SF -36), 
Visual Analogue Scale (VAS ), HIV Treatment Satisfaction 
Questionnaire (HIV -TSQ) and F unctional Assessment of 
Chronic Illness Therap y –Fatigue (FACIT -F).
Efficacy : Primary Endpoint:
HIV-1 RNA <50 copies/mL  at Week 12 using pure virologic 
response (PVR)
Secondary E ndpoint s:
Emergence of n ew mutations in HI V-1 reverse transcriptase and 
integrase (attempted on any  post Day 1 sample with 
HIV-1RNA ≥50 copies/mL )
HIV-1 RNA< 50 copies/mL  at Weeks 24 and 48 using PVR
HIV-1 RNA < 50 copies/ mLat Week s 12, 24 and 48 using the 
FDA snapshot anal ysis (sensitivity  anal ysis)
CD4
+ cell count change from Day  1 at Weeks 12, 24 and 48
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 10 19August 2016Statistical Methods: The primary  endpoint of pure virologic response (PVR) with 
HIV-1RNA < 50 copies/mL  at Week 12 will be computed.
The following c riteria are considered for classify ing subjects as a 
pure virologic responder at Week 12:
Subject remains on study treatment
No confirmed virologic rebound as defined by :
HIV-1 RNA ≥ 50 copies/mL  on 2 consecutive visits
HIV-1RNA ≥ 50 copies/mL  during stud y followed by 
premature discontinuation
Note: For confirmation of viral rebound, the first HIV- 1 RNA 
must occur on or before the upper limit of the Week 12 anal ysis 
window, the confirming event ( i.e.
, the second of the 
consecutive HIV -1 RNAs or premature study  discontinuation) 
can occur after the upper limit of the Week 12 analysis window.
Subjects who meet the above criteria are pure virologic responders 
at Week 12; otherwise subjects are pure virologic failures (PVF) 
atWeek 12.
Similar definition would hold for PVR at Weeks 24 and 48.
Sensitivity  analy ses of virologic failure will use the FDA snapshot 
analysis (and other sensitivity  anal yses such as missing equal 
failure) at Weeks 12, 24 and 48.
An interim efficacy  analy sis will be conducted when the fir st 
50subjects com plete 12 weeks of treatment. Based on the anal ysis 
of the primary  efficacy  variable (HIV -1 RNA < 50 copies/mL ) 
using pure virologic response, study  conduct may  be altered based 
on the recommendations of the internal monitoring committee.
Descriptive statistics will summarize baseline characteristics, 
efficacy , and safet y endpoints.
The primary  anal ysis will desc ribe the point estimate and 
95% confidence interval around the proportion of subjects with 
HIV-1RNA < 50 copies/mL  for the primar y endpoint. Ifthe 
observed pure virologic response rate is 90%, then with 
100 participants, the width of the 95% CI will be ± 5.9% 
(large sample size approximation and binomial distribution) .
This study  will be conducted in accordance with the guidelin es of Good Clinical Practice (GCP) 
including archiving of essential documents.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 11 19August 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
3TC lamivudine
ABC abacavir
AE adverse event
AIDS Acquired Immune Deficiency Syndrome
AhR aryl hydrocarbon receptor
AK adenylate kinase
ALT alanine aminotransferase
ANC absolute neutrophil counts
ANOVA analysis of variance
ARV antiretroviral
AST aspartate aminotransferase
ATR Atripla®; EFV /FTC/TDF
ATV atazanavir
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration versus time curve
AUC last area under the plasma concentration -time curve from time 0 to the last measurable concentration
AUC tau area under the plasma concentration -time curve at the end of the dosing interval
AV atrioventricular
BMD bone mineral density
BUN blood urea nitrogen
CBC complete blood count
CK creatine kinase
CI confidence interval
CL cr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) concentration
of drug
CNS central nervous system
COBI, /co cobicistat
CPK creatine phosphokinase
CRF case report form(s)
CRO contract (or clinical) research organization
CSR clinical study report
CTX type 1 collagen crosslinked C -telopeptide
CYP cytochrome P450
DDI drug-drug interaction
DHHS Department of Health and Human Services
DMC data monitoring committee
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 12 19August 2016DNA deoxyribonucleic acid
DRV darunavir
DSPH Drug Safety and Public Health
DTG dolutegravir
ECG electrocardiogram
EDC electronic data capture
ETR Etravirine
eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
EFV efavirenz
ETR etravirine
EVG elvitegravir
E/C/F/TDF elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg /emtricitabine (FTC) 200 mg /
tenofovir disoproxil fumarate (TDF) 300 mg single tablet regimen
E/C/F/TAF elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg /emtricitabine (FTC) 200 mg /
tenofovir alafenamide (TAF) 10 mg single tablet regimen
ESDD early study drug discontinuation
FAS full analysis set
FDA (United States) Food and Drug Administration
FPV Fosamprenavir
FDC fixed dose combination
FSH follicle -stimulating hormone
FTC emtricitabine
F/TAF emtricitabine/tenofovir alafenamide
FTC/TDF emtricitabine/tenofovir disoproxil fumarate
GCP Good Clinical Practice (Guidelines)
GFR glomerular filtration rate
GGT gamma glutamyl transferase
GSI Gilead Sciences, Inc.
GS-7340 tenofovir alafenamide, TAF, L -Alanine, 
N
-[(S)-[[(1R) -2-(6-amino -9H-purin-9-yl)-1-methylethoxy]methyl]/ phenoxyphosphinyl] -, 
1-methylethyl ester
HAART highly active antiretroviral therapy
HBsAg hepatitis B virus surface antigen serology
HBV hepatitis B virus
HCV hepatitis C virus
HCVAb hepatitis C virus antibody serology
HDPE high-density polyethylene
HIV human immunodeficiency virus
HIV-TSQs HIV Treatment Satisfaction Questionnaire Status
HIV-TSQc HIV Treatment Satisfaction Questionnaire Change
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 13 19August 2016HLGT high-level group term
HLT high-level term
HSP hysterosalpingogram
IB investigator’s brochure
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IND Investigational New Drug (Application)
INSTI integrase strand transfer inhibitor
IMP Investigational Medicinal Product
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
IUS intrauterine hormone -releasing system
IWRS interactive web response system
KS Kaposi’s sarcoma
LAM Lactational amenorrhea method
LDH lactate dehydrogenase
LLN lower limit of the normal range
LLT low-level term
LLOQ lower limit of quantification
LPV lopinavir
MedDRA Medical Dictionary for Regulatory Activities
Mg milligram
Min minute
mmHg millimeters mercury
MVC maraviroc
NNRTI non-nucleoside reverse transcriptase inhibitor
N[t]RTI nucleos(t)ide reverse transcriptase inhibitor
NOAEL no observed adverse effect level
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
NVP nevirapine
P1NP procollagen Type 1 N-terminal propeptide
PBMCs peripheral blood mononuclear cells
PAH pulmonary arterial hypertension
PI protease inhibitor
PK pharmacokinetic
PT preferred term
PVR pure virologic response
PXR pregn ane-X-receptor
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 14 19August 2016QA Quality Assurance
QD once daily
RAL raltegravir
RBC Red blood cells
RNA ribonucleic acid
RPV rilpivirine
RTV , /r ritonavir
SA single agent
SADR serious adverse drug reaction
SAE serious adverse event
SOC system organ class
SOP standard operating procedure
SQV Saquinavir
SSRI selective serotonin reuptake inhibitors
STB Stribild®, EVG/COBI/FTC/TDF (E/C/F/TDF) STR
STR single tablet regimen
SUSAR Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide (GS -7340)
TAFfumarate tenofovir alafenamide fumarate (GS -7340- 03)
TAM thymidine analogue
-associated mutation
TDF tenofovir disoproxil fumarate
TFV tenofovir
TFV -DP tenofovir diphosphate (TFVpp)
Tmax the time (observed time point) of C max
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
US United States
VAS visual analog scale
VR virologic rebound
WBC white blood cells
z terminal elimination rate constant, estimated by linear regression of the terminal 
elimination phase of the serum, plasma concentration of drug versus time curve
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 15 19August 20161. INTRODUCTION
1.1. Background
HIV-1 infection is a life -threatening and serious disease that is of major public health interest 
around the world. There are 35 million people worldwide and approximately  1.1million people 
in the US living with HIV -1.Within Western and Central Europe, it is estimated that there are 
over 900,000 individuals living with HIV and 131,000 new infections in 2012.
The infection, if left untreated or suboptimall y treated, is characterized by deterioration in 
immune function, 
the subsequent occurrence of opportunistic infections and malignancies, 
ultimately  resulting in death. Therapeutic strategies for the treatment of HIV -1 disease have been 
significantl y advanced by the availability  of highly  active anti retroviral therapy  (HAART); 
theintroduction of HAART was associated with a dramatic decrease in acquired immune 
deficiency  syndrome (AIDS) -related morbidity  and mortality .
The primary  goals of ARV therap y for HIV -1 infection are to reduce HIV -associated morbidity  
and prolong the duration and quality  of life, restore and preserve immunologic function, 
maximally  and durabl y suppress plasma HIV viral load, and prevent HIV transmission. 
TheDHHS guidelines list emtricitabine/tenofovir DF (FTC/TDF) as a preferred nucleos(t)ide 
reverse transcriptase inhibitor NRTI /NtRTI backbone in com bination with either 
cobicistat -boosted elvitegravir [EVG/COBI] administered as EVG/COBI/FTC/TDF, raltegravir, 
dolutegravir or darunavir/ritonavir as an initial ARV regimen Although HAART has 
dramatical ly improved the prognosis of patients infected with HIV- 1, eradication of the virus is 
not possible with currently available therapies. Long-term viral suppression and prevention of 
drug resistance are goals of successful therap y. In regimens of comparable efficacy , the total pill 
burden, dosing frequency, and concerns about safety  and side effects are generall y the most 
significant obstacles to achieving high adherence .
Tenofovir disoproxil fumarate (TDF) is a preferred NRTI  among recommended regimens for 
treatment -naïve HIV -positive patients, but is associated with nephrotoxicity  and reduced bone 
mineral density {Panel on Antiretroviral Guidelines for Adults and Adolescents 2016}. 
Lifelong antiretroviral treatment and the increasing comorbidities 
being recognized and treated 
in HIV -positive patients creates an urgent need to improve the safet y profile of regimens that 
most effectivel y suppress HIV replication. Tenofovir alafenamide (TAF) is a novel oral prodrug 
of tenofovir (TFV), a nucleotide anal og that inhibits HI V-1 reverse transcription; TAF was 
recentl y added as a preferred NRTI combination by the DHHS panel {Panel on Antiretroviral 
Guidelines for Adults and Adolescents 2016 }. Gilead has coformulated TAF with the integrase 
strand 
transfer inhibitor elvitegravir (EVG), cobicistat (COBI), and emtricitabine (FTC) into a 
fixed dose combination (FDC). Compared to TDF, the use of TAF in the E/C/F/TAF FDC is 
provides enhanced l ymphatic delivery  of tenofovir, resulting in higher intracellular levels of the 
active phosphory lated moiety  tenofovir -diphosphate, and lower s ystemic circulating levels of 
tenofovir. These features are translated into more F/TAF effective suppression of viral 
replication, and an improved tolerability  and safety  profile , especially  with re spect to renal and 
bone safet y.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 16 19August 2016The prevalence of M184V resistance mutation in reverse tra nscriptase (RT) region in 
HIV-1- infect ed pretreated patients is high {Miller et al 2004 }, {Riddler et al 2008}, {Blanco et 
al 2014
}, {Poon et al 2011}, {Haubrich et al 2007b }. Inaddition, patients with virologic failure 
to the first NNRT -
based regimen will develop the M184V mutation in up to 60% of cases 
{Riddler et al 2008 }, {Marconi et al 2008 }, {Saini et al 2012 }, {Miller et al 2012 }. 
This mutation confers resistance to both FTC a nd 3TC, but not to tenofovir. However FTC may  
provide some benefit on viruses harboring M184V through the reduced viral fitness associated 
with this mutation { Wei et al 2002 }, {Wei et al 2003}, {Deval et al 2004 } . TheM184V mutation 
also sensitizes the viral strain to TFV; viral h ypersensitivity  has been associated with better 
virologic response to regimens that conta in the hypersensitive drug {Haubrich et al 2002}, 
{Whitcomb et al 2002 }, {Shulman et al 2001 }, {Haubrich 2004}, {Haubrich et al 2007a }.
The presence of HIV drug resistance mutations prior to tr
eatment (i.e., transmitted drug resistance)
may affect virologic outcome if the mutation reduces susceptib ility to a drug in the regimen.
Reduced outcome with transmitted resistance has been best demonstrated for the NNRTI and 
INST I based regimens { Gibson et al 2014 }, {Nicot et al 2015}, {Callegaro et al 2014 }, {Li et al 
2013a }, {Li et al 2013b }. However, some mutations, even in the same drug class, may  not 
preclude viral suppression. In an integrated resistance analy sis from the phase 3 E/C/F/TDF 
treatmen
t naïve stud ies, Kulkarni reported that 25% (89/353) had a baseline mutation, with 
9%of subjects having an NRTI  mutation (including TAM s), 2% having PI mutations and 
17% having an NNRTI mutation {Kulkarni et al 2014 }. Subjects with preexisting drug resistance 
mutations achieve d Week 144 HIV -1 RNA < 50copies /mL at rates similar to those without 
mutation (76% versus 78%, respectively ).
To date, switch options in patients harboring isolated NRTI M184V /Imutation are limited. 
PI/r+FTC/TDF is currentl y the preferred choice. Conti nuing a PIr -based regimen raises the 
problem of long -term tolerability  and cardiovascular risk in an aging population. 
Furthermore existing antiretroviral therapies used in this population have a high pill burden. 
Patients ha rboring M184V /Iresistance muta tion cannot benefit from a switch to TDF- based 
FDCs (EFV/FTC/TDF, RPV/FTC/TDF or EVG/COBI/FTC/TDF) because such patients were 
excluded from switch studies with these FDCs . Switching from a PI /r to a n NNRTI -based
regimen, which theoretically  has a lower bar rierto resistance , has been successful with 
RPV/TDF/FTC in the SPIRIT stud y {Palella et al 2014 }. Of 23 subject s with baseline NNRTI 
resistance (K103N), 22/24 (92%) maintained viral suppression at the last follow -up visit. 
Thus, there is precedent to switching from a PI /r regimen to a regimen without aPI with 
continued excellent control of viral suppression.
In ad dition, 4 subject s randomized to receive E/C/F/TDF in the Strategy -PI and Strategy -NNRTI 
protocol s that had M184V mutations at baseline (mutations that were prohibited by  protocol 
entry  criteria and discovered during treatment) achieved 
viral suppression :
Subject 1: M184V, discontinued at Week 4 by medical monitor, HIV RNA < 50 copies /mL
Subject 2: M41L+L210W+T215Y, discontinued at Week 12by the medical monitor ,
HIVRNA < 50 copies /mL
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 17 19August 2016Subject 3: M184V, discontinued at Week 24, HIV RNA < 50copies /mL
Subject 4: M184V, s tayed on study  to Week 96, HIV RNA < 50 copies /mL
TAF is a novel prodrug of tenofovir with a unique metabolism that provides enhanced ly mphoid 
cells delivery  of tenofovir, resulting in a 4 fold increase in intracellular TFV -DP in PBMCs. 
Potentially , these higher intracellular levels of TFV -DP delivered b y TAF may  allow this agent 
to overcome resistance mutations that might decrease TDF potency . In vitro, TAF activity  is 
observed to be better than TDF against NRTI resistant viruses (K65 R, multiple TAMs 
and/or M184V) {Margot et al 2013 }.In patients with limited treatment options because of an 
isolated M184V, E/C/F/TAF could be an option for simplification and could offer an alternative 
for those who cannot tolerate PI/r or who are at high cardiovascular risk.
1.2. Tenofovir Alafenamide (TAF, GS -7340)
1.2.1. General Inf ormation
Tenofovir alafenamide (GS- 7340, TAF, or L -Alanine, 
N-[(S)-[[(1R) -2-(6-amino -9H- purin-9- yl)-1-methy lethoxy ]methy l]/phenoxy phosphiny l]- , 
1-methy lethy l ester) is a second generation oral prodrug of tenofovir (TFV), a nucleotide analog 
that inhibits HIV
-1 reverse transcription. Tenofovir is metabolized intracellularly  to the active 
metabol ite, tenofovir diphosphate (TFV -DP), a competitive inhibitor of HIV -1 reverse 
transcriptase (RT) that terminates the elongation of the viral DNA chain. In the develo pment of 
TAF, three forms of the drug substance have been used in various studies: GS -7340, sy nony mfor 
GS-7340 as the free base; GS -7340 -02,synony m for TAF monofumarate (1:1); and GS -7340-03 
as the hemifumarate (2:1). GS -
7340- 03, also known as TAF fumara te, is considered comparable ,
based on ph ysical/chemical properties, to GS-7340 -02 that has been used in previous studies and 
a number of ongoing studies. GS -7340 -03was also used in the Phase 2 study GS -US-292-0102 
and several Phase 3 studies (for example: GS-US-292- 0104 and GS -US-292-0111). GS - 7340-03 
and GS -
7340- 02 exist asthe free base, TAF (GS -7340), in blood and biological fluids.
For further information, refer to the current Investigator’s Brochure for E/C/F/TAF.
1.2.2.
Preclinical Pharmacology and Toxicology
1.2.2.1. Primary  Pharmacody namics
TAF is metabolized to TFV, a nucleotide analog (i.e., a nucleoside monophosphate analog) 
which is not dependent on an intracellular nucleoside kinase activit y for the first step in the 
conversion to the active metabolite, TFV diphosphate (TFV- DP). The cellular enzy mes 
responsible for TFV metabolism to the active diphosphory lated form are adeny late kinase (AK)
{Robbins et al 1995 }and nucleotide diphosphate kinase, which are highl y active and ubiquitous. 
AK exists 
as multiple isozy mes (AK1 to AK4), with the phosphory lation of TFV mediated most 
efficientl y by AK2.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 18 19August 2016The intracellular metabolism of TAF and TFV are consistent with the 600- fold enhancement in 
anti-HIV activity  in cell culture of TAF over TFV. Metabolism o
f TAF was also studied in 
different human blood l ymphocyte subpopulations, CD4+ and CD8+ T -cells, NK cells, B- cells 
and macrophages/monocy tes. TAF is metabolized inside host cel ls to the active metabolite 
TFV -DP. Concentration of the active metabolite TFV -DP was substantial in all cell populations.
1.2.2.2. Safety  Pharmacology
TAF monofumarate (GS -7430- 02) has been evaluated to determine potential effects on the 
central nervous s ystem (R990188), renal s ystem (R990186), cardiovascular (D2000006) 
andgastrointestinal systems (R990187). Single doses did not induce pharmacologic effects on 
the central nervous s ystem of the rat (1000 mg/kg), the renal sy stem of the rat (1000 mg/kg), 
orthe cardiovascular sy stem of the dog (100 mg/kg). TAF monofumarate (at 1000 mg/kg 
reduc ed distal transit and increased stomach weights starting 2 hours post
-dosing with 
reversibility  beginning by  6 hours after dosing. The NOEL for gastrointestinal motility  was 
100mg/kg. The IC50for the inhibitory  effect of TAF fumarate (GS -7340- 03) on hERG
potassium current was estimated to be greater than 10 μM.
All nonclinical pharmacokinetic experiments in this s ection were performed using 
TAF monofumarate (GS -
7340- 02), and all stud y data described in this section reflect the dosage 
of the monofumarate. For reference, 100 mgof TAF monofumarate i s equivalent to 80 mgof the 
GS-7340 free base (TAF).
Plasma pharmacokinetics of the intact prodrug, TAF, following oral administration o f 
GS-7340 -02 in dogs and monkey s demonstrated rapid absorption with peak plasma concentrations
between 0.25 and 0.5 hours. Peak TFV plasma concentrations occurred following TAF 
absorption, with TFV T maxvalues between 0.25 to 1.7 hours in rats, dogs, and monkey s. 
TFV plasma concentrations declined with a terminal half
-life of 1 1.2 to 16.4 hours in rats 
(fasted), >24 hours in dogs (fasted) and 8.1 to 12.5 hours in rhesus monkey s.
The tissue distribution and recovery  of [14C] radiolabeled GS-7340- 02 was exam ined in 
beagle dogs. Radioactivity  was detected in all tissues except bra in, with the majority  present in 
the contents of the gastrointestinal tract, liver, kidney, and large intestine. Tissue concentrations 
were the highest in kidney, PBMCs, liver, large intestine, and bile. Significant concentrations of 
TFV -related radioactive material were observed in ly
mph nodes suggesting that TAF may  be 
selectivel y cleaved to tenofovir in the cells of the lymphoreticular s ystem. The primary  route of 
elimination of tenofovir is renal excretion of unchanged drug based on IV studies of tenofovir. 
Following oral administration of GS -7340- 02, approximately  15% of a radiolabeled dose is 
recovered in dog urine in 24 hrs. Tenofovir was the major species present in the urine (90%), 
with about 3.4% of TAF also present. Biliary  excretion of tenofovir in dogs and fecal elimination 
of tenofovir in rats and dogs are negligible.
Tenofovir was the only  species found in the intestinal contents and feces. In human sy stems, 
TAF is metabolized by  hydroly tic cleavage and, to a lesser extent, by  CYP3A4 catal yzed 
oxidation (AD -
120-2004). As a result of the limited metabolism of TAF by CYP3A4 inhibition 
or induction of this enzyme should have little consequence on TAF exposure in vivo. TAF has 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 19 19August 2016limited potential to alter CYP enzy me activity  through inhibiti on and does not inhibit UGT1A1 
function. In addition, TAF is not an activator of either the ary l hydrocarbon receptor (AhR) 
orhuman pregnane -X-receptor (PXR). These features combined with the relatively  low plasma 
exposures of TAF in humans suggest that t he potential of TAF to cause or be affected by  
clinically  relevant drug -drug interactions is very  low.
1.2.3. Clinical Trials of E/C/F/TAF
Clinical trials using tenofovir alafenamide, coformulated into the E/C/F/TAF STR include:
Study GS -US-292-0101 was a Phase 1 study  of 40 subject s evaluating the relative 
bioavailability  of two different formulations of E/C/F/TA F STR, each with TAF dose of 
25mgor 40 mg, versus E/C/F/TDF STR or TAF 25 mgalone. Exposures of EVG, COBI, 
and FTC were comparable between E/C/F/TAF v s E/C/F/TDF regardless of formulation 
(monolay er or bi -layer). In contrast, TAF exposures were ~2.2 -fold higher (and corr
esponding 
tenofovir exposures ~ 3-foldhigher) when administered as E/C/F/TAF (25 mg) vs TAF SA 
25mgfor both formulations of the E/C/F /TAF, likely  mediated by  inhibition of 
Pgp-
mediated intestinal secretion of TAF b y COBI.
Study GS -US-292-0103 was a completed Phase 1 healthy  volunteer study ,which evaluated 
the PK and relative bioavailability  of the E/C/F/TAF STR relative to the individual 
components at TAF doses of 10 (STR) or 25 mgSA. Results indicate that when dosed as the 
E/C/F/TAF 10 mgSTR, TAF and TFV exposures were comparable to thos e observed with 
TAF 25 mgdosed alone. Exposures of EVG, COBI, and FTC were also comparable between 
the STR and individually  dosed formulations.
Study GS -US-
292-0102 is a Phase 2 ongoing, randomized, active -controlled study , 
compar ingE/C/F/TAF (10 mg) versus Stribild®(STB, E/C/F/TDF) in treatment -naïve, 
HIV
-1 infected subjects. At Week 48, the E/C/F/TAF demonstrated potent ant iviral efficacy  
(HIV -1RNA < 50copies /mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the 
snapshot algorithm); in the E/ C/F/TAF group, no patient had emergent resistance to 1 or 
more components of the E/C/F/TAF. Importantl y, E/C/F/TAF demonstrated a potential 
benefit over E/C/F/TDF in terms of renal and bone safet y: smaller median decreases in 
eGFR (mL/min) (at Week 48,E/C/F/TAF -5.5 vs E/C/F/TDF - 10.0 [P <0.001) and smaller 
median percentage decreases in BMD (at Week 48, spine E/C/F/TAF - 1.00 vs 
E/C/F/TDF - 3.37 [P <0.001], hip - 0.62 vs - 2.39 [P <0.001]).
Studies GS- US-292-0104 and GS- US- 292-0111 are two Phase 3, controlled, double -blind 
studies 
evaluating treatment- naive HIV -infected patients. These patients were recruited with 
an estimated creatinine clearance of 50 mLper min or higher from 178 outpatient centers in 
16 countries. Patients were randoml y assigned (1:1) to receive E/C/F/TAF or E/C/F/TDF 
with matching placebo. Randomization was done by a computer -generated allocation 
sequence (block size 4) and was stratified b y HIV-1 RNA , CD4 count, and region 
(USA orex-USA). Investigators, patients, study staff, and those assessing outcomes were 
masked to treatment group. All participants who received one dose of stud y drug were 
included in the primary  intention -to-treat efficacy  and safet y analyses. The main outcomes 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 20 19August 2016were the proportion of patients with plasma HI V-1 RNA less than 50 copies permLat 
Week 48 as defined b y the US Food and Drug Administratio n (FDA) snapshot algorithm 
(pre-specified non- inferiority  margin of 12%) and pre-specified renal and bone endpoints at 
48week s. There were 1733 patients who received treatment (866 given E/C/F/TAF 
and867given E/C/F/TDF). E/C/F/TAF was non -inferior to E /C/F/TDF, with 
800(92%) of 866 patients in the TAF group and 784 (90%) of 867 patients in the TDF group 
having plasma HIV -1 RNA less than 50 copies permL(adjusted difference 2.0%, 
95% CI -0.7 to 4.7). Patients given E/C/F/TAF had significantl y smaller mean serum 
creatinine increases than those given E/C/F/TDF (0.08 vs 0.12 mg/dL; p<0.0001), 
significantl y less proteinuria (median %change -3 vs 20; p < 0.0001), and a significantly  
smaller decrease in bone mineral d
ensity  at spine (mean % change -1.30 vs -2.86; p <0.0001)
and hip ( -0.66 vs - 2.95; p <0.0001) at 48 weeks. Interpretation through 48 week s, more than 
90% of patients given E/C/F/TAF or E/C/F/TDF h
ad virologic success. Renal and bone 
effects were significantl y reduced in patients given E/C/F/TAF.
Study GS -US-292-0109 is a phase 3 stud y designed to evaluate the safet y, efficacy , 
andtolerability  of switching to E/C/F/TAF in HIV -infected patients who are virologically  
suppressed on regimens containing TDF. Patients meeting the inclusion criteria of a plasma 
HIV-1 RNA less than 50 copies permLfor ≥ 96 week s on stable TDF -based regimen with 
estimated creatinine clearance > 50 mL/min were randomly  assig ned (2:1) to switch to 
E/C/F/TAF (n =959) or maintain their TDF -based regimen (n =477). The regimens at 
baseline were E/C/F/TDF (n =459), EFV/FTC/TDF (n =376), and RTV -boosted 
ATV +FTC/TDF (n =601). The main outcomes were the proportion of patients with plasma 
HIV-1 RNA less than 50 copies permLat Week 48 as defined b y the US Food and Drug 
Administration (FDA) snapshot algorithm (pre -specified noninferiorit y margin of 12%) 
andpre-specified renal and bone endpoints at 48 week s. In this study  of 1436 virologicall y 
suppressed patients, switching to E/C/F/TAF was non- inferior and statistically superior to 
continuing TDF-based regimen, with 97% of E/C/F/TAF patients and 93% of patients 
maintaining an TDF -based regimen having plasma HIV -1 RNA less than 50 copies permLat 
Week 48 (adjusted difference 4.1%, 95% CI: 1.6 to 6.7). Patients switching to E/C/F/TAF 
had significant improvements in serum creatinine (p < 0.001) and eGFR (p <0.001) 
than those maintaining TDF-based regimen. There were no Grade 2-4 serum creatinine 
increases in patients that switched to E/C/F/TAF. The difference in bone mineral densit y 
changes from baseline to 48 week s significantl y favored the patients switching to E/C/F/TAF 
with increases observed compared maintaining an TDF -based regimens where there 
were decreases i n mean % change in BMD (spine: 
-0.28 vs +1.79; p < 0.001 and 
hip: -0.26 vs +1.37; p <0.001). There were fewer discontinuations due to adverse events in 
the patients switching to E/C/F/TAF compared to contin uing TDF -based regimen 
(0.9% vs2.5%).
GS-US-292-0112, a Phase 3 open- label safet y study of E/C/F/TAF in HIV -1 positive patients 
with mild to moderate renal impairment; Week 48 results demonstrated that patients who 
switched to E/C/F/TAF had no change in eGFR, and had
significant improvements in 
measures of renal function including proteinuria, albuminuria, retinol binding protein and 
beta-2-microglobulin. These subjects also had improvements in measures of bone mineral 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 21 19August 2016density . Importantl y, because FTC was given without dose a djustment to patients with 
eGFR 30-50 mL/min, these patients had comparable safet y profile to patients with 
eGFR 50-69 mL/min, with no increased rate of potential FTC related drug reactions, 
supporting the safet y of FTC at higher exposures. In addition, 92% of study  participants 
maintained virologic suppression (HIV -1 RNA < 50 copies /ml) at 
Week 48 after switching to 
E/C/F/TAF.
1.3. Information A bout Comparator Regimens
There are no comparator regimens in this study ; all subjects will be switched to E/C/F/TAF.
1.4. Rationale for t his Study
The aim of this pilot study is to validate the ability of E/C/F/TAF to maintain virological 
suppression in patients harboring M184V and/or M184I isolated mutation sto NRTI s when 
switching from a TDF -or ABC -based regimen.
1.5. Risk/Benefit Assessment for the Study
Potential risks of a patient’s study  involvement include switching to a new unfamiliar regimen 
with potential loss of virologic control due to underly ing HIV -1 drug resistance, the inconvenience
of more frequent clinical study  visits and laboratory  blood draws, andthe associated pain and 
discomfort of phlebotomy. Risk will be mitigated by careful monitoring for virologic failures in 
real time during the conduct of the study  and revie w by  an internal data monitoring committee. 
Potential benefits may  include the patient receiving a new antiretroviral regimen that is more 
convenient leading to improved adherence, potentially  fewer adverse events than the current 
regimen, gaining access t o E/C/F/TAF when it is not widely  available or currently  covered by  the 
payer/healthcare s ystem,and the knowledge that patient participation will be contributing 
towards a bod y of science.
1.6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 22 19August 20162. OBJECTIVES
The primary  objective of this study  is:
To evaluate the efficacy  of E/C/F/TAF fixed dose combination (FDC) after switching from a 
stable regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent in 
maintaining HIV -1 RNA <
50copies /mL at Week 12(using pure virologic response ) 
insubjects harboring the archived NRTI resistance mutation M18 4V and/or M184I  in 
HIV-1reverse transcriptase
The secondar y objectives of this study are:
To determine the safet y and tolerability of E/C/F/ TAF F DC in subjects switching from 
2NRTI  plus third antiretroviral agent regimens
To evaluate the development of new resistance mutations in subjects who develop virologic 
failure after switching to E/C/F/TAF FDC
To determine the durability  of efficacy  at Weeks 24 and 48 in maintaining 
HIV-1RNA < 50 copies /mL using pure virologic response (PVR)
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 23 19August 20163. STUDY  DESIGN
3.1. Study Design
This protocol describes a n open- label, single arm, multicenter , two part study  to evaluate the 
efficacy  and safet y of switching to E/C/F/TAF FDC in HI V-1 infected adult subjects who are 
virologicall y suppressed (HIV-1 RNA < 50 copies /mL)harbo ring an archived isolated 
M184V and/or M184I mutation and who ha ve been on a stable regimen consisting of FTC/TDF 
or ABC/3TC plus a third antiretroviral agent for ≥ 6 consecutive months prior to screening.
Both Part 1 and Part 2 will consist of subjects who have a documented presence of 
M184V and/or M184I mutations (mixtures are acceptable) in reverse transcriptase .
In Part 1, the first 50 subject s will have M184V and/or M184I  (mixtures are acceptable) 
inreverse transcriptase WI THOUT an yother NRTI  resistance mutation (including thy midine 
analogue -associated mutatio ns (TAMs) [M41L , D67N, K70R, L 210W, T215Y/F, 
andK219Q/E/N/R] , K65R, K70E, T69 insertion , and/orQ151M mutation complex [A62V, V75I,
F77L, F116Y, Q151M] .See Table 3-1.
If the rate of virologic failure in Part 1 
is deemed acceptable , once the internal DMC officiall y 
completes the interim review the study  will continue to Part 2 (with the expanded entry  criteria) .
In Part 2, the second 50subject s will have M184V and/or M184I (mixtures are acceptable) 
inreverse transcriptase WITHor WITHOUT 1or 2thymidine analog -associated mutations.
Evidence of K65R, K70E, T69insertion, and/orQ151M mutation complex in subjects in addition 
to the resistance mutations above will not be el igible for entry  into the study .See Table 3-1.
Table 3-1. Part 1 and Part 2 Resistance Criteria
Part 1 Part 2
Inclusion Resistance Mutations
TAMs 0from : 0, 1,or 2 from :
M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R
Exclusion Resistance Mutations
NRTI-R Any from:
K65R, K70E, T69 insertion ,Q151M m utation complex
[A62V, V75I, F77L, F116Y, Q151M]
Primary PI -R Any
Primary INSTI -R Any
Additional Allowed Resistance Mutations
NRTI-R Any not defined above
NNRTI -R Any
TAM = thymidine analogue -associated mutation ; NRTI = nucleos(t)ide reverse transcriptase inhibitor ; PI = protease inhibitor; 
INSTI = integrase strand transfer inhibitor ; NNRTI = nonnucleoside reverse transcriptase inhibitor ; -R = resistance
E/C/F/TAF 
Protocol GS-US-292-182 4 Final 
Gilead Sciences , Inc. Amendment #1 
Figure 3-1. Study Schema 
Screening 
::;42 days 
Prior to 
Baseline Day 1 Week 12 
(Prima1y Endpoint) 
I 
48 Weeks of Treatment on E/C/F/TAF 
(n = approximately 1 oot Week48 
30-Day 
Follow-upb ,c 
a Follo wing the Day 1 visit, subjects will retum for study visits at Weeks 4, 8, 12, 16, 24 36 and 48. 
b After 48 weeks, subjects will stop study drug and complete a 30-Day Follow-up visit to end their participation in the study. 
c Subjects who discontinue study drug administration before their Week 48 visit, \..,i.11 complete and ESDD visit. 
TI1ese subjects may remain on the study off study chug up to the Week 48 visit. Upon comple tion ofWe -ek 48 visit, 
subjects may be required to retum to the clinic for a 30-Day Follow -up visit to complete their participation in the study . 
3.2. Study Treatments 
Subjects who provide written consent and meet all eligibility criteria will switch from their 
cunent regimen consisting ofFTC /TDF or ABC /3TC plus a third antiretroviral agent to 
E/C/F/TAF FDC on Day 1. 
Allowed third agents include LPV /r, ATV+RTV , ATV+COBI , DRV +RTV , DRV+COBI , 
FPV + RTV , SQV + RTV , ATV(no booster) EFV , RPV , NVP , ETR , RAL or DTG. See 
Table 4- 1. 
3.3. Duration of Treatment 
The study will consist of a 42-day screening period (within 42 days before Day 1 visit) , 
followed by a 48 week treatment period. After Day 1, subjects will return for study visits at 
Weeks 4, 8, 12, 16, 24, 36 and 48. 
After Week 48, subjects will stop study drug and complete a 30-Day Follow-up visit. 
3.4. End of Study 
End of study is defined as completion of the 48 weeks of treatment and the 30 Day Follow-Up 
visit. 
3.5. Post Study Care 
After a subject has completed/te1minated their paiiicipation in the study , long-te1m cai· e for the 
subject will remain the responsibility of their primaiy treating physician. 
CONFIDENTIAL Page 24 19 August 2016 
EICIFITAF 
Protocol GS-US-292 -1824 
Gilead Sciences , Inc. 
3.6. Source Data 
Gilead will provide source docume nt worksheets for all study visits. 
3.7. Sample s for Optional Exploratory Assessment s 
CONFIDENTIAL Page 25 Final 
Amendment # 1 
19 August 2016 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 26 19August 20164. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Approximately  100 subject s who meet the eligibility  criteria will be enrolled.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)The ability  to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures .
2)Age ≥ 18 years
3)Documented historical genoty pe report showing M184V and/or M184I (mixtures are 
acceptable) in reverse transcriptase . Subjects m ust not have an y primary  INSTI or primary  PI 
resistance mutation s present on historical genot ype; 
NNRTI mutations are allowed.
Proviral DNA test must not have additional exclusion resistance mutations against PI s, 
NRT Is and INSTIs. See Table 3-1.
Part 1 (first 50 subject s):Historical genot ype report must show M184V 
and/or M184I  
in reverse transcriptase WITHOUT any other NRTI resistance mutation 
(including thymidine analogue -associated mutations (TAMs) [ M41L , D67N, K70R, 
L210W, T215Y/F, and K219Q/E/N/R] , K65R, K70E, T69 ins ertion and Q151M mutation 
comple x[A62V, V75I , F77L , F116Y, Q151M]). See Table 3 -1.
Part 2 (after the interim efficacy review
– 50 subject s):Historical genoty pe report 
must show M184V and/ or M184I in reverse transcriptase WITHor WITHOUT one or 
two thy midine analogue -associated mutations (TAMs) [ M41L , D67N, K70R, L 210W, 
T215Y/F, and K219Q/E/N/R ]. Evidence of K65R, K70E, T69insertion and /or
Q151M mutation complex [A62V, V75I , F77L, F116Y, Q151M] will not be eligible .
SeeTable 3-1.
4)Currently  receiving an antiretroviral regimen consisting of FTC/TDF or ABC/3TC in 
combination with one third 
antiretroviral agent for ≥ 6consecutive months preceding the
Screening Visit .Refer to Table 4-1for allowed third agents of the pre -existing regimen
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 27 19August 20165)Documented plasma H IV-1 RNA levels < 50 copies /mL for ≥ 6month s preceding the
screening visit (measured at least twice using the same assay ).
a)In the preceding 6 month s prior to screening, one ep isode of “blip” (HIV -1 RNA 
> 50 and < 400 copies /mL) is acceptable, onl y if HIV- 1 RNA is < 50 copies/mL  
immediately  before and after the “blip.”
b)
To determine virologic suppression in the preceding 6 month s prior to screening, the 
lower limit of quantification (LLOQ) b y the local HIV -1 RNA assay  may  be used, onl yif 
its LLOQ is greater than 50 copies /mL (e.g. LLOQ of 75 copies /mL) .
6)Plasma HIV -1 RNA levels < 50 copies /mL at Screening Visit
7)Normal ECG (or if abnormal, determined b y the Investigator to be not clinically significant)
8)Estimated glomerular filtration rate ≥ 30mL/min accordin g to the Cockcroft- Gault formula 
for creatinine clearance (eGFR CG) {Coc kcroft et al 1976 }:
Male: (140 −age in years) (wt in kg) CL cr(mL/min)
72 × (serum creatinine in mg/dL)
Female: (140 −age in years) (wt in kg) 0.85  CL cr(mL/min)
72 × (serum creatinine in mg/dL)
9)Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)
10)Total bilirubin ≤ 1.5 mg/dL, and normal direct bilirubin (sub jects with documented 
Gilbert’s syndrome or with atazanavir -associated hy perbilirubinemia may  have total bilirubin 
up to 5 ×ULN as long as direct bilirubin is normal )
11)Adequate hematologic function (absolute neutrophil count ≥1,000/mm3; 
platelets ≥50,000/mm3; hemoglobin ≥ 8.5 g/dL)
12)A female subject is eligible to enter the stud y if it is confirmed that she is:
a)Not pregnant confirmed by  a negative serum pregnancy  test,which is required for female 
subjects (unless permanently  sterile or greater than two years post -menopausal)
b)Of non -childbearing potential (e.g., women who have had a hy sterectomy , have had both 
ovaries removed or medically  documented ovarian failure, or a re postmenopausal women 
> 54 years of age with cessation (for ≥12 month s) of previousl y occurring menses)
c)Female subjects who have stopped menstruating for ≥ 12 month s but do not have 
documentation of ovarian hormonal failure must have a serum follicle sti mulating 
hormone (FSH) level at screening within the post- menopausal range based on the 
Central Laboratory  Reference range.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 28 19August 2016d) Of childbearing potential and agrees to utilize the protocol specified method of 
contraception or be non -heterosexually  active or practice sexual abstinence from 
screening throughout the duration of study  treatment and for 30 days following 
discontinuation of study  drugs (as defined in Appendix 5)
e)Female subjects who utilize hormonal contraceptive as one of their birth control method s 
must have used the same method for at least three month s prior to study  dosing.
13)Male subjects must agree to use the protocol specified method (s)of contraception during 
heterosexual intercourse or be non
-heterosexually  active, or practice sexual abstinence from 
screening throughout the study  period and for 30 days following the last study  drug dose.
a)Male subjects must agree to refrain from sperm donation from first dose until at least 
30days after the last study  drug dose.
Table 4-1. Allowable Third Antiretroviral Agents of Pre -Existing Regimen
Antiretroviral Class Agents
Boosted PI LPV/ra, ATV+RTVa, ATV+COBIa(or ATV/COBIaFDC), 
DRV+RTVa, DRV+COBIa(or DRV/COBIaFDC)
FPV+RTV, SQV+RTV , ATV(no booster)
NNRTI EFV, RPV, NVP , ETR
INSTI RAL, DTG
a Change of pharmacoenhancer between RTV and COBI in itself, including change from PI+RTV to PI/COBI, is not 
considered as change of regimen .
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
14)Subjects will have no evidence of previous virologic failure on a PI /r or INSTI -based 
regimen (with or without resistance to either class of ART ). Subjects may  have evidence of 
prior virologic failure on only  an NNRTI plus 2 NRTI -based regimen.
15)Subjects on a current PI /r-based regimen will have no evidence of p revious use of an y 
approved or experimental integrase strand transfer inhibitor (I NSTI) (for any  length of time) .
16)A new AIDS -defining condition diagnosed within the 30 days prior to screening 
(except CD4 cell count and/or percentage criteria) (refer to Appendix 6)
17)
Hepatitis C infection that would require therapy  during the study
18)Hepatitis B surface antigen (HBsAg) positive
19)Subje cts 
with clinical evidence of decompensated cirrhosis (e.g., ascites, encephalopathy , 
variceal bleeding, etc.)
20) Females who are breastfeeding
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 29 19August 201621)Positive serum pregnancy test
22)Have an implanted defibrillator or pacemaker
23)Current alcohol or substance use judged by the Investigator to potentiall y interfere with 
subject study  compliance
24)A history  of malignancy  within the past 5 years (prior to screening) or ongoing malignancy  
other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non -invasive 
cutaneous squamous carcinoma. Subjects with cutaneous KS are eligible, but must not have 
received an y systemic therapy  for KS within 30 days of Day 1and must not be anticipated to 
require s ystemic therapy  during the study
25)Active, serious infections (oth er than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap y within 30 days prior to Day 1
26)Any other clinical condition or prior therapy  that, in the opinion of the I nvestigator, would 
make the subject unsuitable for the stud y or unable t o comply  with dosing requirements
27)Participation in any  other clinical trial (including observational trials) without prior approval 
from the sponsor is prohibited while participating in this trial
28)Subjects receiving ongoing therap y with an y of the medicati ons in Table 4-2and those listed 
in Section 5.4, including drugs not to be used with EVG, COBI, FTC or TAF (For EVG, 
COBI, and FTC 
refer to the individual agents Presc ribing Information; for TAF refer to t he 
E/C/F/TA F FDC Investigator ’sBrochure) ; or subj ects with an y known allergies to the 
excipients of E/C/F/TAF FDC tablets.
Table 4-2. Disallowed Agents
Drug Class Agents Disalloweda
Alpha Adrenergic Receptor Antagonists Alfuzosin
Calcium Channel Blockers Bepridil
Anticonvulsants Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine
Antihistamines Astemizole, Terfenadine
Antimycobacterials Rifampin, Rifapentine, Rifabutin
Ergot Derivatives Ergotamine, Ergonovine
Dihydroergotamine
Methylergonovine
Ergometrine
GI Motility Agents Cisapride
Herbal/Natural Supplements St. John’s Wort, Echinacea
Inhaled Beta Agonist Salmeterol
HMG -CoA Reductase Inhibitors Simvastatin, Lovastatin
Neuroleptics Pimozide
Phosphodiesterase -5 Inhibitors Sildenafil (for PAH)
Sedatives/Hypnotics Orally administered Midazolam, Triazolam
a Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 30 19August 20165. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Enroll ment
This is an open -label, single arm study .All subjects will receive open -label E/C/F/TAF.
Subjects will be assigned a screening number at the time of consent. Investigators must consult 
with the Medical Monitor and receive written approval p rior to re -screening subjects.
Prior to enrollment to Day 1, the historical genotype report andproviral DNA resistance 
testresult must be reviewed 
and approved by Gilead and subject eligibility confirmed.
Once eligibility  has been confirmed by Gilead , each subject will be assigned a unique subject 
number using anInteractive Web Response Sy stem (I WRS). Once a subject number has been 
assigned, it will not be reassigned to an y other subject. The subject number assignment may  be 
perform ed up to 3 days prior to the in -clinic Day 1 visit provided that all screening procedures 
have been completed and subject eligibility  has been confirmed.
Eligibility and allDay 1visit tests and procedures must be completed prior to the 
administration of the first dose of study drug.
TheIWRS will assign open -label stud y drug bottle numbers at each stud y visit. Study  drug will 
be dispensed to the subjects in an open -label fashion. Initiation of treatment with the study  drug 
must take place within 24 hours after the Day 1 visit.
5.2. Description and Handling of E/C/F/TAF FDC
5.2.1. Formulation
E/C/F/TAF FDC tablets are capsule -shaped, film -coated green tablets and are debossed with 
“GSI” on one side of the tablet and “510” on the other side of the tablet. E/C/F/TAF tablets 
contain 150 mgof EVG, 150 mgof COBI, 200 mgof FTC, and 10 mgof TAF (as 11.2 mgof 
TAF fumarate). The E/C/F/TAF tablet core contain s silicon dioxide, croscarmellose sodium, 
hydroxypropylcellulose, lactose monohy drate, magnesium stearate, microcry stalline cellulose, 
and sodium laury l sulfate as inactive ingredients and are film -coated with indigo carmine 
aluminum lake, polyethylene glycol, polyvin yl alcohol, talc, ti tanium dioxide, and 
yellow ironoxide.
5.2.2. Packaging and Labeling
E/C/F/TAF FDC tablets are packaged in white, high densit y poly ethylene (HDPE) bottles. 
Each bottle contains 30 tablets, silica gel desiccant and poly ester material. Each bottle is 
enclosed with a white, continuous thread, child -resistant poly propy lene screw cap with an 
induction
-sealed , aluminum- faced liner.
Study drug(s) to be distributed to centers in participating countries shall be labeled to meet 
applicable requirements of the EU Guideline to Good Manufacturing Practice −Annex 13 
(Investigational Medicinal Products), and/or other local regulations.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 31 19August 20165.2.3. Storage and Handling
E/C/F/TAF tablets should be stored at controlled room temperature of 25 °C (77 °F); excursions
are permitted between 15 °C and 30 °C (59 °F and86°F). Storage conditions are specified on 
the label. Until dispensed to the subjects, all bottles of study  drugs should be stored in a securely
locked area, accessible only  to authorized site personnel.
To ensure the stabilit y and proper identification, study drug should not be stored in a container
other than the container in which they  were supplied .
Consideration should be given to handling, preparation, and disposal through measures that
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct
eye contact or exposure through inhalation when handling.
5.3. Dosage an d Administration of E/C/F/TAF FDC
E/C/F/TAF FDC tablets will be provided by  Gilead Sciences.
E/C/F/TAF FDC tablets containing 1 50mgof EVG, 150 mgof COBI, 200 mgof FTC, and 
10mgof TAF will be provided to all eligible subjects at Day 1. Study  drug will be administered 
orally  at approximately  the same time each daywith food.
Subjects will be instructed to bring all stud y medication in the original container at each clinic 
visit for drug accountability  (unless otherwise specified in the st udy procedures sections of 
thisprotocol).
5.4. Prior and Concomitant Medications
Subjects receiving hormonal contraceptives should consider additional methods of 
contraception as concentratio ns of ethiny l estradiol may decrease and progestin level may  
increase on co -administ ration with study  drug.
The use of medications for the treatment of HIV, other than study  drug, is prohibited.
Subjects receiving concomitant m edications that are highl y dependent on CYP3A for 
clearance and for which elevated plasma concentrations are associated with serious adverse 
events should consider alternative concomitant m edications.
During the study , subjects may  not receive any  of the following concomitant medications:
Competitors of renal excretion (e.g., probenecid; high -dose non -steroidal 
anti-inflammatory  drugs)
Known nephrotoxic drugs (e.g., aminogly cosides, amphotericin B, vancomy cin, 
cidofovir, foscarnet, cisplatin and pentamidine)
Medications listed in the following table and use of herbal/natural supplements are excluded 
or should be used with caution while subjects are participating in the stud y. Any concomitant 
medication requiring adjustment or discontinuation due to renal impairment or a change in 
renal function on study  should be managed per that drug’s prescribing information.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 32 19August 2016Table5-1. Prior and Concomitant Medications
Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
Acid Reducing Agents
AntacidsConcentration of study drug may decrease w ith 
antacids. Subjects may not take antacids 
(e.g.,Tums, Mylanta); the ulcer medication 
sucralfate (Carafate); or vitamin or mineral 
supplements that contain calcium, iron or zinc for a 
minimum of 2 hours before and 2 hours after any 
dose of study drug.
Alpha Adrenergic Receptor 
AntagonistsAlfuzosin
Analgesics Tram adol, Propoxyphene:
Concentrations may increase with study drug(s); 
clinical monitoring is recommended.
Antiarrhythmics Amiodarone, Flecainide Quinidine, Propafenone, 
Systemic Lidocaine, Mexiletine, Disopyramide:
Concentrations may increase with study drug(s) 
resulting in a potential for cardiac arrhythmias; 
clinical and ECG monitoring is recommended.
Calcium Channel Blockers Bepridil Felodipine , Nifedipine, Nicardipine, Verapamil, 
Diltiazem, Amlodipine:
Concentrations may increase with study drug(s). 
Clinical an d ECG m onitoring of subjects 
isrecommended
Digoxin Digoxin:
Concomitant use may result in increased levels; 
use with caution and with appropriate monitoring 
of serum digoxin levels. Digoxin therapy should 
be initiated at the lower dose, and the dose should 
be titrated to clinical response.
Antibacterials Clarithromycin and Telithromycin : 
Concentrations may be altered w ith study drug( s); 
consider an alternative.
Anticoagulants Warfarin:
Concentrations may increase or decrease w ith 
study drug(s); appropriate INR 
(International Norm alized Ratio) monitoring 
isrecommended.
Anticonvulsants Phenobarbital, Phenytoin, 
Carbamazepine, 
OxcarbazepineEthosux imide, Divalproex, Lamotrigine:
Concentrations may increase with study drug(s); 
clinical monitoring is recommended.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 33 19August 2016Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
Antidepressants Selective serotonin reuptake inhibitors (SSRIs):
Adose reduction may be required for most drugs 
of this class with the exception of sertraline.
Tricyclics:
Concentrations may increase or decrease w ith 
study drug(s). Concentration monitoring is 
recommended to ensure adequate 
clinical response.
Trazod one:
Concomitant use with CYP3A inhibitors results 
in increased concentrations and adverse events; 
dose reduction should be considered.
Antifungals Ketoconazole and Itraconazole:
Concomitant use with study drug may result in an 
increase in concentrations. Daily dose of 
ketoconazole and itraconazole should b e 
restricted to 200 mg. Subjects receiving 
ketoconazole or itraconazole should be monitored 
for adequate clinical response.
Voriconazole:
Concomitant use with study drug may result in an 
increase in concentrations. Clinical monitoring 
may be needed.
Antigout Colchicine:
Concentrations may increase with study drug(s). 
Dose reductions of colchicine may be required. 
Should not be coadministered in patients with 
renal or hepatic impairment.
Treatment of Gout Flare:
0.6mg(1 tablet) × 1 dose, follow ed by  0.3mg
(half tablet) 1 hour later. Treatment course may 
be repeated no earlier than 3 days.
Prophylaxis of Gout Flares :
If the original regimen was 0.6 mgtwice a day, 
the regimen should be adjusted to 0.3 mgonce 
aday. Ifthe origi nal regimen was 0.6 mgonce 
aday, the regimen should be adjusted to 0.3 mg
once every other day.
Treatment of Familial Mediterranean Fever :
Maximum daily dose of 0.6 mg
(may be given as 0.3 mgtwice a day).
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 34 19August 2016Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
Antihistamines Astemizole, Terfenadine
Antimycobacterials Rifampin, Rifapentine, 
Rifabutin
β-Blockers Metoprolol, Timolol:
Clinical and ECG monitoring of subjects is 
recommended. A dose decrease may be needed.
Corticosteroids: Inhaled/Nasal Concomitant use of inhaled fluticasone and study 
drug(s) may increase plasma concentrations of 
fluticasone. Use is not recommended unless the 
potential benefit to the subject outweighs the risks 
of corticosteroid side effects. Alternatives should 
be considered, particularly for long -term use.
Corticosteroids: Systemic Systemic dexamethasone, a CYP3A inducer, 
may significantly decrease elvitegravir and 
cobicistat plasma concentrations, which may 
result in loss of therapeutic effect and 
development of resistance. Alternative 
corticosteroids shou ld be considered.
Use of Prednisone as a steroid burst ( ≤ 1week
ofuse)should be monitored appropriately.
Endothelin Receptor Antagonists Bosentan:
Coadm inistration may lead to decreased 
elvitegravir exposures and loss of therapeutic 
effect and develo pment of resistance. 
Alternative endothe lin receptor antagonists may 
beconsidered.
Ergot Derivatives Ergotamine, Ergonovine
Dihydroergotamine
Methylergonovine
Ergometrine
GI Motility Agents Cisapride
Herbal/Natural Supplements St. John’s Wort, Echinacea
HMG- CoA Reductase Inhibitors Simvastatin, Lovastatin Atorvastatin :
Concentrations may increase with study drug(s). 
Start with the lowest dose; gradual increase in 
dose may be tailored to clinical response. Careful 
monitoring for signs and symptom s of muscle 
weakness or myopathy, including rhabdomyolysis.
Immunosuppressants Cyclosporine, Rapamycin, Sirolimus, Tacrolimus: 
Concentrations may increase with study drug(s). 
Therapeutic monitoring should be considered.
Inhaled Beta Agonist Salmeterol
Neuroleptics Pimozide Perphenazine, Risperidone, Thioridazine:
A dose decrease may be needed.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 35 19August 2016Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
Opiates Methadone:
Methadone exposures are unaffected upon 
coadministration with elvitegravir and cobicistat. 
No dose adjustment of methadone is required 
upon coadministration with study drug(s).
Meperidine (Pethi dine):
Dosage increase and long -term use are not 
recommended due to increased levels of 
metabolite normeperidine, which has analgesic 
and CNS stimulant ( e.g.,seizures) activities.
Buprenorphine:
Concentrations of buprenorphine and 
norbuprenorphine are modestly increased and 
concentrations of naloxone are modestly decreased 
when coadministered with elvitegravir and 
cobicistat, with no effect on opioid 
pharmacodynimcs. Theconcentration changes are 
not considered clinically relevant and no dose 
adjustment of buprenorphine/naloxone is required 
upon coadministration with study drug(s).
Phosphodiesterase -5 Inhibitors Sildenafil (for PAH) Pulmonary Arterial Hypertension :
Tadalafil:
Caution should be exercised, including 
consideration of dose reduction, when 
coadministered for treatment of pulmonary 
arterial hypertension.
Erectile Dysfunction :
Silden afil, Vardenafil, Tadalafil:
It is recommended that a single dose of Sild enafil 
no more than 25 mgin 48 hours, Vardenafil no 
more than 2.5 mgin 72 hours, or Tadalafil no 
more than 10 mgin 72 hours be coadministered.
Sedatives/Hypnotics Orally administered 
Midazolam, TriazolamBuspirone, Clorazepate, Diazepam, E stazolam, 
Flurazepam, Zolpidem:
A dose decrease may be needed for these drugs. 
Clinical monitoring is recommended.
Should subjects have a need to initiate treatment with any  disallowed concomitant 
medication, the Gilead Sciences M edical M onitor must be consulted prior to initiation of the 
new medication. In instances where an excluded medication is initiate d prior to discussion 
with the Sponsor, the Investigator must notify  Gilead Sciences as soon as he/she is aware of 
the use of the disallowed medication.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 36 19August 20165.5. Account ability ofStudy Drug
The Investigator is responsible for ensuring adequate accountability  of all used and unused study  
drug. Accountability  records (Study  Drug Inventory  Log) will be provided to each study  site in 
order to:
Record the date received and th e quantity  of study  drug bottles.
Record the date, subject n umber, subject initials, the study  drug bottle number dispensed.
Record the date, quantity of used and unused study drug returned b y the subject, along with 
the initials of the person recording th e information.
The Investigator [or designee (e.g., stud y center pharmacist)] will acknowledge receipt of the 
study  drugs from Gilead Sciences (or designee) after reviewing the shipment’s content and 
condition. The Investigator (or designee) will be respon sible for maintaining an accurate 
inventory  of the dates and quantities of all study  drugs received, dispensed, and returned. 
Subjects should be instructed to return all unused study  drug to the site at their study  visits.
Each dose of the study  drug admin
istered at the study  center will be administered by  qualified 
study  center personnel. All doses of study  drug administered to subjects in the clinic under the 
supervision of staff will be accuratel y recorded on the Study  Drug Inventory  Logs provided by  
Gilead Sciences (or on equivalent documentation maintained by  the study  center), which indicates
the date and quantit y of all doses of study  drug dispensed to individual subjects. The requirements
of all applicable drug dispensing laws will apply  to all doses of study  drugs dispensed by  the 
Investigator (or designee).
The study  drug inventory log must be available for inspection by  the study  monitor. 
Study medication supplies, including partiall y used or empty bottles, must be accounted for b y 
the study  monito r prior to destruction or return.
5.5.1. Study Drug Return or Disposal
The study  monitor will provide instructions for return. If return is not possible, the study  monitor 
will evaluate each stud y center’s study  drug disposal procedures and provide appropriate 
instruction for destruction of unused study  drug . If the site has an appropriate standard operating 
procedure (SOP) for drug destruction as determined by  Gilead Q uality  Assurance (QA) , the site 
may destroy  used (empty or partiall y empt y) and unused study  drug bottles in accordance with 
that site’s approved SOP. A cop y of the site’s approved SOP will be obtained for central files.
If study  drug is destro yed on site, the investigator must maintain accurate records for all study  
drug destroy ed. Records must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and the person who disposed of the study  drug . Upon study  completion, 
copies of the study  drug accountability  records must be filed at the site. Another copy will be 
returned to Gilead. The study  monitor will review study  drug 
bottles and associated records at 
periodic intervals.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 37 19August 20166. STUDY  PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows.
Any deviation from protocol procedures should be noted in the subject’s clinical chart and 
appropriate electronic Case Report Forms (eCRFs). In addition, t he sponsor or 
Contract Research Organization (CRO) should be p romptly  notified of an y protocol deviations.
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the I nvestigator to ensure that the subject is eligible prior to enrollment.
Subjects who provide written consent and meet all eligibility  criteria will receive 
elvitegravir 150mg/ cobicistat 150 mg/ emtricitabine 200 mg/ tenofovir alafenamide 10 mg
(E/C/F/TAF), on Day 1. Please refer to Section 5.1for details about enrollment and treatment 
assignment.
6.2. Pretreatment Assessments
6.2.1. Screening 
Visit
Subjects will be screened within 42days before enrollment ( Day 1)to determine eligibility  for 
participation in the study . The following will be performed and documented at screening:
Obtain written informed consent
Obtain medical history , including history  of HIV -1 disease -related events, cigarette smoking
(current or previous smoker) , diabetes, family cardiovascular history and prior medications 
within 30 days of the S creening Visit
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature)
Height and weight
12-lead ECG performed supine
Urine collection for the following laboratory  analy ses:
Urinaly sisand Urine chemistry
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 38 19August 2016Blood sample collection for the following laboratory  anal yses:
Serum pregnancy  test (females of childbearing potential only ). If the test is positive, 
thesubject will not be enrolled.
FSH test is required for female subjects (age > 54 years) who have stopped menstruating 
for > 12 month s but do not have documentation of ovarian hormonal failure.
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chlo ride, creatinine, 
glucose, potassium andsodium
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
(eGFR CG){Cockcroft et al 1976 }:
Male: (140 –age in years) ×(wt in kg) = CL cr(mL/min)
72 ×(serum creatinine in mg/dL)
Female: (140 –age in years) ×(wt in kg) 0.85 = CL cr(mL/min)
72 ×(serum creatinine in mg/dL)
Hematology  profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HI V-1 RNA
Hepatitis B virus surface antigen serology  (HBsAg)
Hepatitis C virus (HCVAb) serology (reflex HCV RNA is performed in subjects with 
positive HCVAb serology)
Whole blood sample collection for proviral genotype anal ysis of archived resistance
Review of concomitant medications
Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form.
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 42 days after screening for the Day 1 assessments .
From the time of obtaining informe
d consent through the first administration of study  drug , 
record all serious adverse events (SAEs), as well as any  adverse events related to 
protocol -mandated procedures on the adverse events 
electronic case report form (eCRF). 
Allother untoward medical o ccurrences observed during the screening period, including 
exacerbation or changes in medical history are to be captured on the medical history  eCRF. 
See S ection 7Adverse Events and Toxicity  Management for additional details.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 39 19August 20166.2.2. Day 1Visit
Eligible historical genotype report and subsequent proviral genotype test result for 
archived
resistance must both be reviewed and approved by Gilead to confirm subject 
eligibility .Once subject ’s full eligibility  is confirmed, t he following evaluations are to be 
completed at the Day 1 Visit. The subject must complete all Day 1 assessments before being 
dispensed the study  drug. I nitiation of treatment with the study drug must take place within 
24hours after the Day 1 visit.
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs (blood pressure, pulse, respiration rate, and temperature), including weight
Urine collection for the following labo ratory  procedures:
Urinaly sis and urine chemistry
Urine pregnancy  test (females of childbearing potential only ). If the urine pregnancy  test 
is positive at Day 1 visit, study  drug will not be dispensed. The positive result will be 
confirmed with a serum pr egnancy  test. If the serum pregnancy  test is positive, the subject
will not be able to participate.
Urine sample storage for possible additional clinical testing
Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: a lkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, potassium andsodium
Cystatin C testing
Metabolic assessments: Fasting (no food or drinks, exce pt water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL  and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the 
metabolic assessments.
Estimated GFR, according to the Cockcroft- Gault formula for creatinine clearance
Hematology  profile: CBC with differential and platelet count
Plasma 
HIV-1RNA
EICIFITAF 
Protoco l GS-US-292-1824 
Gilead Sciences , Inc. 
- CD4+ cell count 
- P lasma s ample storage for safety and virology testing Final 
Amendment # 1 
• Qu estionnaires: Subject is to read questio nnaire by her/himself and write/mark answe rs 
directly onto questio nnaire. 
-Visual Analog Scale (VAS) 
- H IV Treatment Satisfaction Questio nnaire Status (HIV-TSQs) 
-EQ-5D 
-Med ical Outco me Study Sho1i Foim-36 (SF-36) 
- F unctional Assess ment of Chronic Illness Therapy -Fatig ue (F ACIT-F) 
• S tudy diu g dispensation. Study diug will be dispensed in an open-labe l fashion. 
Subjects must initiate dosing of study diu g within 24 hours after the Day 1 visit. 
• Su bjects should be instructed to take E/C/F/TAF FDC t ablets once daily with food at the 
same time each day. Subjects should also be counseled regarding the impo1iance of 
adherence and taking their study medications at approx imately the same time each day. 
6.3. Treatment Assessment s 
6.3.1. Treatment Visits (Weeks 4 -48) 
The following evaluations are to be completed at the end of Weeks 4, 8, 12, 1 6, 24, 36 and 48 
unless othe1wise specified. 
All study visits are to be scheduled relati ve to the Day 1 vis it date . Study visits are to be 
completed within± 2 days of the p rotoco l-specified visit date through Week 16 and complet ed 
within± 6 days of the p rotocol -speci fied visit date through Week 36, unless othe1 w i se speci fied. 
The visit window at Wee k 48 will be± 6 weeks of the protocol-sp ecified visit date, which 
coincides with t he Week 48 statistica l analysis window for HIV- 1 RNA. For the purposes of 
sched uling the Week 48 visit, a ± 6 day window of the p rotoco l-specified visit date should be 
used. 
Regularly scheduled evaluations wi ll be made on all subjects whet her or n ot they continue to 
receive study diug. 
CONFIDENTIAL Page40 19 August 2016 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 41 19August 2016Note: At the Week 16 visit, the only assessment s to be completed are:
Review of AEs and changes in concomitant medications
Blood sample collection for the following laboratory  analyses:
Plasma HIV -1 RNA
Plasma sample storage for safet y and virology testing
Document study  drug dispensation an d accountability  for all study  drug dispensed.
Questionnaire: Subject is to read questionnaire b y her/himself and write/mark answers 
directly  onto questionnaire .
Visual Analog Scale (VAS)
For all other visits, please complete the following:
Review of AEs a nd changes in concomitant medications
Complete phy sical examination ( Weeks 24 and 48 ) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator)
Symptom -directed phy sical examination as needed ( Weeks 4, 8, 12 and 36)
12-lead ECG performed supine ( Week 48 only )
Vital signs (blood pressure, pulse, respiration rate, and temperature), including weight
Urine collection for the following laboratory  procedures:
Urinaly sis and urine chemistry
Urine pregnancy test (females o f chil dbearing potential only );positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued.
Urine sample storage for possible additional clinical testing
Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, potassium andsodium .At Weeks 24 and 48, analyses of glucose will be done 
as part of the fasting metabolic assessments and not as part of the chemistry profile .
EICIFITAF 
Protocol GS-US-292 -1824 
Gilead Sciences , Inc. Final 
Amendment # 1 
-Metabolic assessme nts: Fasting (no food or drinks, except wate r, at least 8 hours prior to 
blood collectio n) glucose and lipid panel (total cholesterol, HDL, direct LDL 
and triglycer ides). If the subject has not fasted prior to the visit , the visit may proceed , 
but the subject must return within 72 hours in a fasted state to draw blood for the 
metabolic assessme nts (Wee ks 24 and 48). 
-Estimated GFR, according to the Cockcroft -Gault fonnu la for creat inine cleara nce 
- H emato logy profi le: CBC with differe ntial and platelet count 
-Plasma HIV -I RNA 
-CD4 + cell count 
-Plasma samp le storage for safety and virology testing 
• Subjects who meet the criteria for virolog ic rebound shou ld be managed accord ing to 
Manageme nt ofVirolog ic Fai lure (Section 6.8). 
• H IV-I geno/phenotype resistance testing for subjects with unconfomed virologic rebou nd 
with HIV-I RNA value~ 50 copies /mL (Week 48 only) 
• Quest ionnaires: Subject is to read questionnai re by her/himself and write/mark answe rs 
directly onto questionnaire. 
-Visu al Analog Scale (VAS) (Weeks 4, 8, 12, 24, 36 and 48) 
- H IV Treatme nt Satisfact ion Questio nnaire Change (HIV -TSQc) (Wee ks 4, 24, and 48) 
-EQ-5D (Weeks 24 and 48) 
-SF-36 (Weeks 24 and 48) 
-FACIT -F (Weeks 24 and 48) 
• Docume nt study chug dispe nsation (Weeks 4, 8, 12, 24, and 36) and a ccou ntabi lity for all 
study chug dispe nsed. 
CONFIDENTIAL Page42 19 August 2016 
EICIFITAF 
Protocol GS-US-292-1824 
Gilead Sciences , Inc. 
6.4. 
6.4.1. Post-treatment Assessment s 
Earl y Stud y Drug Discontinuation (ESDD ) Visit Final 
Amendment # 1 
If a subject disco ntinu es study drng prior to the Week 48 visit, the subj ect will be asked to return 
to the clinic within 72 hours of stopping study diug for the ESD D visit. The subject will be asked 
to continu e attend ing the scheduled study visits through Week 48. 
At the ESDD Visit, any evaluation s showing abnormal re sults indicating that there is a 
possible or probable causal relation ship with the study drug. will be repeated weekl y 
(or as often as deemed prudent by the Inve stigator) until the abnormality is resolved , 
return s to baseline , or is otherwi se explained. 
The following evaluations are to be complet ed at the Early Study Drng Disco ntinuation Visit: 
• R eview of AEs and changes in concomitant medicatio ns 
• Comp lete physica l examination (urogenital/a norecta l exams will be perfo1med at the 
discretion of the Investigato r) 
• 12-lead ECG perfo1med supine 
• Vital signs (blood press ure, pulse, respiratio n rate, and temperatu re), including weight 
• Urine collectio n for the following laborato1y proced ures: 
-Urinalysis and urine chemistiy 
- Ur ine pregnancy test (females of chil dbear ing potentia l only); positive urine pregna ncy 
tests will be confnmed with a sernm test. 
- Ur ine sample storage for possible additio nal c linical testing 
• Blood sample collectio n for the following laborato 1 y analyses: 
-Cheinistiy profile: alkaline phosphatase, AST , ALT, total bilirnbin, direct and indirect 
bilirnb in, total protein, albuinin , bicarbonate , BUN, calcium, chloride, creatinin e, 
glucose, potassium and sodium 
-Estimated GFR, acco rding to the Cockcroft-Gault fonnula for creat inine cleara nce 
- H ematology profile: CBC with differential and platelet count 
- P lasma HIV-1 RNA 
-CD4+ cell count 
- P lasma sample storage for safety and virology testing 
CONFIDENTIAL Page43 19 August 2016 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 44 19August 2016Questionnaire : Subject is to read questionnaire by  her/himself and write/mark answers 
directly  onto questionnaire .
Visual Analog Scale (VAS)
HIV-TSQc
HIV-1 genot ype/phenot ype resistance testing for subjects with unconfirmed virologic 
rebound with HIV -1 RNA value 
≥ 50copies /mL
Questionnaire : Subject is to read questionnaire by  her/himself and write/mark answers 
directly  onto questionnaire .
HIV Treatment Satisfaction Questionnaire Change (HIV -TSQc)
Study drug accountability
6.4.2. 30- Day Follow -upVisit
Subjects who complete the study  through the Week 48 visit will be required to return to the 
clinic 30 days after the completion of study  drugs for t he 30 -Day Follow -Up Visit.
Subjects who permanently discontinue stud y drug and refuse to continue study  visits through 
Week 48 will be asked to return to the clinic after the completion of the ESDD visit for a 30 -Day 
Follow -Up visit.
Those subjects who per manently discontinue study drug and continue in the study through 
at least one subsequent visit after the Early Study Drug Discontinuation Visit will not be 
required to complete the 30 -Day Follow -Up Visit.
For the purpose of scheduling a 30 -Day Follow -Up Visit, a ± 6 days window may  be used. 
Thefollowing evaluations are to be completed at the 30 -Day Follow -Up Visit:
Review of AEs and changes in concomitant medications
Symptom -directed phy sical examination as needed
Vital signs (blood pressure, pulse, r espiration rate, and temperature), including weight
Urine collection for the following laboratory  procedures:
Urinaly sis and urine chemistry
Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, potassium andsodium
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 45 19August 2016Hematology  profile: CBC with differential and platelet count
Plasma HI V-1RNA
CD4+ cell count
At the 30 -Day Follow Up Visit, any  evaluations showing abnormal results believed to be a 
reasonable possibility  of a causal relationship with the study  drug will be repeated weekly  
(orasoften as deemed prudent by  the Investigator) until the abnormality  is resolved, 
returns to 
baseline, or is otherwise explained.
6.5. Assessments for Premature Discontinuation from Study
If a subject discontinues study  dosing (for example, as a result of an AE), every  attempt should 
be made to keep the subject in the study  (see Section 6.6, Criteria for Discontinuation of 
Study Treatment) and continue to perform the required study -
related follow-up and procedures. 
If this is not possible or acceptable to the subject or Investigator, the subject may  be withdrawn 
from the study .
6.6. Criteria for Discontinuation of Study Treatment
Study  drug may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree .Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator
Unacceptable toxicity , ortoxicity  that, in the judgment of the investigator, compromises the 
ability  to continue study -specific proced ures or is considered to not be in the subject ’s best 
interest
Lack of efficacy  (virologic failure)
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 5
Discontinuation of the study  at the requ est of Gilead, a regulatory  agency  or an 
institution alreview board or independent ethics committee (I RB/IEC)
EICIFITAF 
Protocol GS-US-292-1824 
Gilead Sciences , Inc. 
6.7. 
6.7.1. 
6.8. Other Evaluation s 
Blood and Urine Storage 
Virologic Failure Final 
Amendment # 1 
Subjects who exper ience virologic rebound (VR), as defined below, will be considered to have 
virologic failure. 
Subjects will be considered to have virologic rebound if they have two consecutive confmned 
HIV-1 RNA test results of~ 50 copies/mL at a scheduled or unscheduled visit. 
6.8.1. Management of Virologic Failure 
• If the viral load is 50 copies /mL, HIV-1 RNA shou ld be repeated at a scheduled or 
unsched uled visit 2-4 weeks after the date of the or iginal test with HIV-1 RNA 
50 copies/mL. 
• Upon confinn ation of HIV-1 RNA 50 copies /mL, potential causes of virolog ic failure 
shou ld be documented. Assess ments should inclu de: 
- A dherence 
-Concomita nt medica tion 
-Comorbidities (for example: active substance abuse, depressio n, other 
intercmrent illnesses) 
• Investigators shou ld discuss the manage ment of all subjects with confmned virolog ic failure 
with the Med ical Monitor. 
• If virologic failure is confnmed at the scheduled or unscheduled visit and H IV-1 RNA is 
50 copies/mL, the bl ood samples from the confnma tion vis it will be used for HIV-1 
genotype /phenotype testing. 
CONFIDENTIAL Page46 19 August 2016 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 47 19August 2016If genot ype/phenot ype resistance to study  drug is documented, study  drugs should be 
discontinued.
If no resistance is detected from genot ype/phenot ype testing , subject may  remain on study  
drug and a repeat HIV -1 RNA should be repeated (2 -4 weeks from the date of confirmed test 
with HIV
-1 RNA ≥ 50 copies/mL ). Investigators should carefull y evaluate the benefits and 
risks of remaining on study drug for each individual subject and document this assessment in 
the onsite medical record. Investigators who opt to discontinue study  drugs for an individual 
subject must discuss with the Medical Monitor prior to study  drug discontinuation.
Please refer to Figure 6-1for the management of subjects who meet the criteria for 
virologic failure.
6.8.2.
Resistance Analysis at Subjects Last Visit
Subjects with HI V-1 RNA < 50 copies /mL could experience unconfirmed blips of HIV -1 RNA 
≥
50copies /mL at their last study  visit . Such su bjects will be anal yzed for resistance if the 
unconfirmed rebound happens at Week 48 or at the last visit while taking study  drug
(orwithin 72hours of discontinuation of study  drug ).
EICIFITAF 
Protocol GS-US-292-1824 Final 
Gilead Sciences , Inc. Amendment #1 
Figure 6-1. Management ofVirologic Failure 
Screening Treatment Period 30-Day Follow-up 
Day l 
Unconfirmed 
virologic 
rebound: remain 
on study drug• At any vis it, a rebound in HIV-I RNA to l!:: 50 copies /mL 
Return for scheduled/un scheduled lllV-I 
RNA and potential genotype /phenotype 
(2-4 week5 later ) 
Confmned virologic 
reboundb 
Remain on study 
IDV-I genotype /phenotype' 
If no reverse transc1-ipta se, p1·otease , 
01· integ1·ase resistance detected , 
continue on study drug or current 
regimen. Repeat HIV-I Ri"'JA' If reverse transcripta se, p.-otea se, or 
integra se 1·esistance detected , 
discontinue study d.-ug 01· current 
regimen and construe .I a new 
ARV regimen• 
a If virologic rebound is not confirmed , the subject will remain on the study drug. 
b If virologic rebound is confumed , and the HIV-1 RNA is 2:: 50 copies /ml,, the HIV-1 genotype and phenotype 
(reverse transcriptase , protease and integra se resistance) will be analyzed. 
c Based on the results of the genotype /phen otype assays , the subjec t will remain or discontinue study drug . 
If genotypin g/phenotyping assay fails, a new ARV regin1en may be configmed at the discretion of the Investigator in 
consultatio n with the Medical Monitor. 
d If no resistance detected , HIV-1 RNA will be repeated (2-4 weeks later). Investigator revie ws study drug 
continuati on/discontinuation options and discusse s with Medical Monitor prior to discontinuation. 
e A new ARV regimen will be configtu·ed , at the Investigato r's discretion, and the subjec t will remain in the study. 
CONFIDENTIAL Page48 19 Augu st 2016 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 49 19August 20167. ADVERSE E VENTS AND TOXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which 
does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal prod uct.AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, andtransfusion.
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occu rred (e.g., hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  CRF .
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 50 19August 2016Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of 
medically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions th
at do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edicall y important e vent and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (e .g., clinic al chemistry , hematology , and urinaly sis ) 
thatrequire medical or surgical intervention or lead to study  drug interruption, modification, 
or discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, 
laboratory  or other abnormal assessments (e .g., electrocardiogram, x -rays, vital signs) that are 
associated with signs and/or sy
mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory  
abno rmality  is part of a sy ndrome, record the s yndrome or diagnosis (e .
g., anemia), not the 
laboratory  result (i .e., decreased hemoglobin).
For specific information on handling of clinical laboratory  abno rmalities in this study , 
please refer to Appendix 3.
7.2. Assessment of Adverse Events and Serious Adverse Events
The i
nvestigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to study  
drug therapy  using clinical judgment and the following considerations:
No:Evidence exists that the adverse event has an etiology  other than the study  drug . 
ForSAEs, an alternative causality  must be provided (e .g., pre -existing condition, underly ing 
disease, intercurrent illness, or concomitant medication).
Yes:There is reason
able possibility  that the event may  have been caused by the study  drug .
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 51 19August 2016It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting.
The relationship to study  procedures (e.g., invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures (e.g.,venipun cture )
.
7.2.2. Assessment of Severity
Severity  should be recorded and graded according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may  not be in agreement with the grading of 
the laboratory
 abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for Collection Prior to Study  Drug Initiation
After informed consent, but prior to initiation of study  drug, the following ty pes of events should 
be reported on the eCRF :
All SAEs and adverse events related to protocol -mandated procedures
Adverse Events
Following initiation of study  drug, collect a ll AEs, regardless of cause or relationship, until 
4week s after last administration of study  drug must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ondthe 
protocol defined follow up 
period.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (i.e., signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow -up period, must be reported to the 
CRF/eCRF database and Gilead Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol
-associated procedures perfor med after informed 
consent is signed.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 52 19August 2016Any SAEs and deaths that occur within 30- days of the last dose of study  drug , regardless of 
causality , should also be reported.
Investigators are not obligated to activel y seek SAEs after 
the protocol defined follow up period; 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of study  drug , he/she should promptly  document and 
report the event to Gilead DSPH .
All AEs and SAEs wil l berecorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline
s.
At the time of study  start, SAEs will be reported using an electronic SAE (eSAE) system. 
Gilead will notify  sites in writing and provide training an d account information prior to 
implementing an eSAE system.
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , i.e., 
theeCRF database is not functioning, record the SAE on th e paper serious adverse event 
reporting form and submit within 24 hours as described below .
As soon as it is possible to do so, any
 SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guideline s.
If an SAE has been reported via a paper form because the eCRF database has been locked, 
nofurther action is necessary .
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the
eCRF completion guideline.
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
For fatal or life -threa tening events, copies of hospital case reports, autops y reports, and other 
documents are alsoto be submitted by e-mail or fax only when requested and applicable. 
Transmission of su
ch documents should occur without personal subject identification , 
maintain ingthe tra ceability  of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
EICIFITAF 
Protoco l GS-US-292 -1824 
Gilead Sciences , Inc. Final 
Amendment # 1 
• Any medications necessaiy for ti·eatme nt of the SAE must be recorded onto the concom itant 
medicat ion section of the su bject's CRF /eCRF and the event description section of the SAE 
fo1m. 
Serious Adverse Event Pape r Repo1i ing Process 
• A ll SAEs will be recorded on the serious adverse event report fo1m and submitted by faxing 
or emailing the r epo1i fo1 m within 24 hours of the investigato r 's knowledge of the event to 
the attentio n of Gilead DSPH or to the designated CRO. 
Gilead Scienc es DSPH Fax: 
E-mail: 
7.4. Gilead Reportin g Requirem ents 
Depe nding on rel evant local legislatio n or r egulations, including the applicab le US FDA 
Code of Federal Regu lations, the EU Clinical Trials Directive (2001/20/EC) and relevant 
updates, and other country -spec ific legislatio n or r egulations, Gilead may be required to exped ite 
to worldwide regulato1y agencies repo1is of SAEs , serious adverse drng reactio ns (SADR s), or 
suspected unexpected serious adverse reactio ns (SUSARs) . In acco rdance with the 
EU Clinical Trials Direct ive (2001/20/EC), Gilead or a specified designee will notify worldwide 
regulato1y agencies and the relevant IEC in concerned Membe r States of applicable SUSARs as 
outlined in cmTe nt regulations. 
Assessme nt of expectedness for SAEs will be dete1mined by Gilead using reference safety 
info1matio n spec ified in the investigato r's broc hure or releva nt local label as applicable. 
All investigators will receive a safety letter notify ing them of relevant SUSAR repo1is associated 
with any study drng. The invest igator should notify the I RB or IEC of SUSAR reports as soon as 
is pract ical, wh ere this is required by local regu lato1 y agencies, and in acco rdance with the local 
institutio nal policy. 
7.5. Toxicity Management 
All clinical and clinically significa nt laborato 1 y toxicities will be managed accord ing to unifo1 m 
guidelines detailed in Appendix 3, as outlined below: 
• C linical events and clinically significant laborato 1 y abnonnalities will be graded acco rding to 
the GSI Grad ing Scale for Sever ity of Adverse Events and L aborato 1 y Abno1malities 
(Appendix 4). 
• Grade 3 and 4 clinically significa nt laborato 1 y abno1malities shou ld be confinned by repeat 
testing within 3 calendai · days of receipt of results and before study drng discont inuation, 
unless such a delay is not consistent with good medical practice. 
CONFIDENTIAL Page 53 19 August 2016 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 54 19August 2016Any questions regarding toxicity  management s hould be directed to the 
Gilead Medical Monitor.
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the Investigator.
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade 3 clinically  significant laboratory  abnormality  or clinical event, study  drug may  be 
continued if the event is considered to be unrelated to study  drug.
For a Grade 3 clinical event, or clinicall y significant laboratory abnormality confirmed b y 
repeat testing, that is considered to be related to study  drug, study  drug should be withheld 
until the toxicity  returns to ≤Grade 2. When restarting study  drug following resolution of the 
advers e event, the study  drug should be restarted at full dose upon discussion with the 
Medical Monitor.
If a laboratory  abnormality  recurs to ≥ Grade 3 following rechallenge with study  drug and is 
considered related to study  drug, then study  drug should be perm anentl y discontinued and the 
subject managed according to local practice. Recurrence of laboratory  abnormalities 
considered unrelated to study  drug may  not require permanent discontinuation but requires 
discussion with the Medical Monitor.
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event
For a Grade 4 clinical event or clinicall y significant Grade 4 laboratory abnormalit y 
confirmed b y repeat testing that is considered related to study  drug, study  drug should be 
permanentl y discontinued and the subje ct managed according to local practice. The subject 
should be followed as clinically  indicated until the laboratory  abnormality  returns to baseline 
or is otherwise explained, whichever occurs first. A clinically  significant Grade 4 laboratory  
abnormality  that is not confirmed by  repeat testing should be managed according to the 
algorithm for the new toxicity  grade.
Study  drug may  be continued without dose interruption for a clinicall y non -signi ficant 
Grade 4 laboratory  abnormality  (e.
g., G rade 4 CK after st renuous exercise, or triglyceride 
elevation that is nonfasting or that can be medically  managed) or a clinical event considered 
unrelated to stud y drug requires discussion with the Medical Monitor.
7.5.4. Management of Potential Nephrotoxicity
Estimated glomerula r filtration rate, according to the Cockcroft -Gault ( eGFR CG)formula for
creatinine clearance, will be followed post -baseline during the study . All subjects with estimated 
eGFR CG< 30mL/min must have serum creatinine measured again within 3calendar days of 
receipt of results. At the time of this repeat serum creatinine assessment, Cystatin C will also be 
measured and the eGFR by  CKD -EPI (cystatin C) will be calculated and compared with the 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 55 19August 2016baseline measurement. Any  subjects who have an estimated eGFR CG< 30mL/min that also 
experience > 20% reduction in eGFR by  CKD -EPI (cy statin C) from baseline or who have other 
clinical and/or laboratory evidence of acute renal failure will be discussed with the 
Medical Monitor and may  discontinue from study  drugs. For s ubjects with eGFR CG<
30mL/min 
who are not discontinued based on toxicity management procedures above and considered to 
have stable renal function per Principal Investigator and Medical Monitor, it is not mandatory  to 
repeat eGFR assessments within 3 days
.
CKD -EPI (cystatin C) formula adjusted for age and sex:
eGFR (mL/min/1.73m2) = 133 × min(Scy s/0.8, 1)−0.499× max (Scys/0.8, 1)−1.328× 0.996Age
[×0.932 if female]
where Scy s is serum cy statin C (mg/L), min (Scy s/0.8,1) indicates the minimum of Scys/κ or 1, 
and max (Scy s/0.8,1) indicates the maximum of Scy s/κor 1. All subjects with a change from 
baseline serum creatinine of ≥ 0.4 mg/dL must have serum creatinine repeated, with a concurrent 
urinaly sis and urine chemistry , within two week s ofreceipt of re sults. If a subject has a 
confirmed change from baseline serum creatinine of ≥ 0.4 mg/dL, the Medical Monitor should be 
notified and a consultation with a nephrologist should be obtained.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose , reports 
of adverse events associated with product complaints ,occupational exposure with an AE, AEs in 
infants that occur while breastfeeding, and pregnancy  reports regardl ess of an associated AE.
Medication error is an y unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse 
is defined as an y intentional andinappropriate useof a medicinal p roduct tha t is not in 
accordance with the protocol instructions or the local prescribing information .
An overdose is defined as an accidental or intentional administration of a quantity  of study  drug
given per administration or cumulatively  which is above the maximum recommended dose as 
perprotocol or in the product labelling (as it applies to the daily  dose of the subject in question).
In cases of a discrepancy in drug accountabilit y, overdose will be established only when it is 
clear that the subject has taken the excess dose(s). Overdose cannot be established when the 
subject cannot account for the discrepancy  except in cases in which the investigator has reason to 
suspect that the subject has taken the additional dose(s).
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 56 19August 2016Product complaint associated with an adverse event is defined as complaints arising from 
potential deviations in the manufacture, packaging, or distribution of the medicinal product
associated with an adverse event, which is any untoward medical occurrence in a study  subject 
administered a pharmaceutical product, which does not necessaril y have a causal relationship 
with the study  drug.
Occupational exposure with an AE is defined as exposure to a medicinal product as a result of 
one’s professional or non -professional occupation .
7.6.2. Instructions for Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The investigator should report pregn ancies in female study  subjects that are identified after 
initiation of study  drug and throughout the stud y, including the post study drug follow -up period, 
to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy .
Refer to the eCRF completion guidelines for full instructions on the mechanism of pregnancy  
reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premat ure terminat ion of pregnancy  (e.g., a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons
) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEterm.
Aspontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
Section 7.3.Furthermore, any  SAE occurring as an adverse pregnancy  outcome post study must 
be reported to Gilead DSPH.
The subject should receive appropriate moni
toring and care until the conclusion of the 
pregnancy. The outcome should be reported to Gilead DSPH using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead DSPH. Gilead DSPH contact information is as follows: 
Email:  and Fax: .
Pregnancies of female partners of male stud y subjects are not collected for E/C/F/TAF protocols.
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
PPD
PPD
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 57 19August 20167.6.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to GileadDSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  drug and/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications.
S
pecial situations involving non-Gilead concomitant medications does not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form.
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to 
the eCRF completion guidelines for full instructions on the mechanis m of special 
situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, a nd outcome will be reported, when available.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 58 19August 20168. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is as follows:
To evaluate the efficacy  of E/C/F/TAF fixed dose combination (FDC) after switching from a 
stable regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent in 
maintaining HIV -1 RNA <
50copies /mL at Week 12(using pure virologic response ) 
insubjects harboring the archived NRTI resistance mutat ion M184V and/or M184I  in 
HIV-1reverse transcriptase
The secondary  objectives of this study  are as follows:
To determine the safet y and tolerability of E/C/F/ TAF F DC in subjects switching from 
2NRTI  plus third antiretroviral agent regimens
To evaluate the development of new resistance mutations in subjects who develop virologic 
failure after switching to E/C/F/TAF FDC
To determine the durability  of efficacy  at W eeks 24 and 4 8 in maintaini ng 
HIV-1RNA < 50 copies /mL using pure virologic response (PVR)
8.1.2. Primary Endpoint
The primary  endpoint is the proportion of subjects with HI V-1 RNA <50 copies/mL at Week 12 
as defined b y pure virologic response .
8.1.3. Secondary Endpoint
The secondary endpoints are the pr oportion of subjects with:
Emergence of new mutations in HI V-1 reverse transcriptase and integrase (attempted on any  
post Day 1 sample with HIV -1 RNA ≥ 50 copies/mL )
HIV-1 RNA< 50copies /mL at Weeks 24 and 48 using PVR
HIV-1 RNA < 50 copies /mLat Weeks 12, 24 and 48 using the FDA snapshot analy sis 
(sensitivity  anal ysis)
CD4+ cell count change from Day 1 at Weeks 12, 24 and 48
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 59 19August 20168.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. Efficacy
8.2.1.1.1. Full Anal ysis Set (FAS)
The Full Anal ysis Set will include all the subjects who were randomized and received at least
one dose of stud y drug. The FAS will exclude subjects with major protocol violations 
(e.g., not having the correct historical mutation at study  entry ). The FAS analy sis set is the 
primary analysis set for 
the efficacy  analyses.
8.2.1.2. Safety
The primary  anal ysis set for safety anal yses is defined as all subjects that received at least one 
dose of study  drug .
All data collected during treatment will be included in the safet y summaries .
8.3. Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be su mmarized using standard descriptive 
methods
.
Demographic summaries will include sex, race/ethnicity  and age.
Baseline data will include a summary  of body  weight, height, body  mass index, risk factors for 
HIV
-1 infection .
8.4. Efficacy Analysis
8.4.1. Primary Analysis
The primary  endpoint of pure virologic response (PVR) with HI V-1 RNA < 50 copies /mL at 
Week 12 will be computed.
The following criteria are considered for classify ing subjects as a pure virologic responder at 
Week 12:
Subject remains on study treatment
No confirmed rebound as de fined b y:
HIV-1 RNA ≥ 50 copies/mL  on 2 consecutive visits;
HIV RNA ≥ 50 copies /mL during study  followed by  premature discontinuation of study
Note: For confirmation of viral rebound, the first HIV- 1 RNA must occur on or before the 
upper limit of the Week 12 anal ysis window, the confirming event (i .e., the second of the 
consecutive HIV -1 RNAs or premature study  discontinuation) can occur after the upper limit 
of the 
Week 12 anal ysis window .
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 60 19August 2016Subjects who meet the above criteria are pure virologic responders at Week 12; otherwise 
subjects are pure virologic failures (PVF) at Week 12. The 95% CI will be computed using 
normal approximation to the binomial proportions of PVR
8.4.2. Secondary Analyses
A similar definition to the primary  endpoint will be used for computin g PVR at Weeks 24 and 48.
Sensitivity  analy ses of virologic failure using the FDA snapshot algorithm at Weeks 12, 24 and 48
(and other sensitivity  analy ses such as missing equal failure) will also be conducted.
8.5. Safety Analysis
All safet y anal yses will be performed using the safety  anal ysis set.
All safet y data collected on or after the date that study  drug was first dispensed up to the date of 
last dose of study  drug plus 30 days will be summarized. Data for the pretreatment will be 
included in data listin gs.
8.5.1. Extent of Exposure
A subject’s extent of exposure to study  drug will be generated from the study  drug 
administration data
. Exposure data will be summarized.
Duration of exposure to study  drug will be expressed as the number of week s between the first 
and last dose of the stud y drug, inclusive, regardless of temporary  interruptions in study  drug 
administration
,and summarized. Dosing information for individual subjects will be listed.
8.5.2. Adverse Events
Clinical and laboratory  adverse ev ents will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Treatment -emergent adverse e vents are adverse events that meet one of the following criteria :
Adverse e vents with onset dates on or after the first dose date of study  drug, and no later than 
30days after permanent discontinuation of study  drug, or
Adverse e vents that result in permanent study  drug discontinuation.
Summaries (number and percentage of subjects) of treatment -emergent adverse events 
(bySOC and PT) will be provided. Additional summaries will include summaries for adverse 
events by  grade, Investi gator’s assessment of relationship to study drug, and effect on study  drug 
dosing.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 61 19August 20168.5.3. Laboratory Evaluations
Selected laboratory  data will be summarized us ing onl y observed data. Absolute values and 
change sfrom baseline at all scheduled time points will be s ummarized.
Graded laboratory  abnormalities will be defined using the GSI Grading Scale for S everit y of 
Adverse Events and Lab oratory  
Abnormalities ( Appendix 4).
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
one toxicity  grade from baseline at an y time post baseline up to the date of last dose of study  
drug plus 30 days, will be summarized. If baseline data are missing, then any  graded abnormality  
(i.e., at least a Grade 1) will be considered treatment emergent. The maximum toxicity  grade will 
be summarized by  laboratory  parameter.
Laboratory  abnormalities that occur before the first dose of study  drug or after the subject has
been discontinued from treatment plus 30 days will be included in a data listi ng.
8.5.4.
Other Safety Evaluations
Weight will be summarized by  visit.
Safety  ECGs will be listed and summarized for subjects in the Safet y Analysis Set. Thenumber 
and percent of subjects with abnormal safet y ECG will be summarized by  visit.
8.6. Sample Size
The pri mary  anal ysis will describe the point estimate and 95% confidence interval around the 
proportion of subjects with HIV
-1RNA < 50 copies/ mLfor the primary  endpoint. Ifthe 
observed pure virologic response rate is 90%, then with 100 participants, the width of the 
95% CI will be ± 5.9% (large sample size approximatio n and binomial distribution).
8.7.
Data Monitoring Committee
An internal data monitoring committee (I nternal DMC) , independent of the study  team, will 
review the progress of the study  and perform interim reviews of safet y, efficacy data and provide 
recommendation to Gilead whether the efficacy  and the nature, frequency , and severit y of 
adverse effects associated with study  drug warrant the earl y termination of the study  in the best 
interests of the participants, whether the study  should continue as planned, or the study should 
continue with modifications . The committee will convene after the first 50 subjects enrolled 
complete Week 12 of the study .Based on the analy sis of the primary  efficacy  variable 
(HIV-1RNA < 50 copies /mL) using pure virologic response, stud y conduct may  be altered based 
on the recommendations of the internal monitoring committee.
The I nternal DMC’s specific activities will be defined by  a mutually  agreed charter, which will 
define the I nternal DMC’s membership, conduct and meeting schedule.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 62 19August 20169. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent w ith the European Union 
Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, 
asoutlined in 21 CFR 312, subpart D, “Responsibilities of Spons ors and I nvestigators,” 
21 CFR, P art50,"Protection of Human Subjects" ,and 21 CFR, P art56, "I nstitutional Review 
Boards" .
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54,
"Financial Disclosure b y Clinical I nvestigators" , providing documentation of their financial 
interest or arrangemen ts with Gilead, or proprietary  interests in the investigational drug under 
study . This documentation must be provided prior to the investigator’s (and any  subinvestigator’s)
participation in the study
. The investigator and subinvestigator agree to notify  Gilead of any  
change in reportable interests during the study  and for 1 year following completion of the study . 
Study  completion is defined as the date when the last subject completes the protocol -defined 
activities.
9.1.2. Institutional Review Board (IRB)/Indepen dent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC . The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
theIRB/IEC any modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC 
approval, with the ex ception of those necessary  to 
reduce immediate risk to study  subjects.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 63 19August 20169.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. 
Theinvestigator must use the most current IRB/IEC approved consent form for documenting 
written informed consent. Each informed consent (or assent as appl icable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by  IRB or IEC or 
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintaine d and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Spo nsor, I RB orIEC, or laboratory . Laboratory  
specimens must be labeled in such a way as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions. NOTE :The 
investigator must keep a screening log showing codes, names, and addresses for all subjects 
screened and for all subjects enrolled in the trial. Subject data will be processed in accordance 
with all applicable regulations.
The investigator agrees that all information received fr om Gilead, including but not limited to the 
investigator brochure, this protocol ,eCRF , the study  drug , and any  other study  information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and thereafter. 
This information is no t to be disclosed to any third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent t he 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be full y documented and the study data to be subsequently verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB or IEC and governmental approval with correspondence, informed consent, drug records, 
staff curriculum vitae and authorization forms, and other appropriate documen ts and 
correspondence.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 64 19August 2016The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, i .e., history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled ;
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results 
of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of study  drug , including dates of
dispensing andreturn;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region ( i
.e., United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is dis continued and regulatory  
authorities have been notified. Investigators may  be required to retain documents longer if 
specified 
by regulatory  requirements, by  local regulations, or b y an agreement with Gilead. 
Theinvestigator must notify  Gilead before dest roying any clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the stud y site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection . When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 65 19August 20169.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for t his function is documented according to study  procedures. TheeCRF should 
be completed on the dayof the subject visit to enable the sponsor to perform cent ral monitoring 
of safet y data. The Eligibility  Criteria eCRF should be completed onl y after all data related to 
eligibility  have been receive d. Subsequent to data entry , a study  monitor will perform source data 
verification within the EDC sy stem. Original entries as well as an y changes to data fields will be 
stored in 
the audit trail of the sy stem. Prior to database lock (or any interim time points as 
described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the infor mation in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. S ystem-generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  the monitor or internal G ilead staff, 
who routinely  review the data for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the ori ginal entry , and providing the reason 
for the u
pdate (e.g. data entry  error). At the conclusion of the trial, Gilead will provide the site 
with a read -only archive copy  ofthe data entered by  that site. This archive must be stored in 
accordance with the re cords retention requirements outlined in Section 9.1.5 .
9.1.7. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors , to IECs, or to regulatory  authorit y or health authority  
inspectors.
9.1.8. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifi cations can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency (ies). 
Gilead will ensure that the report meets the standards set out in the I CH Guideline for Structure 
and Conte nt of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be 
prepared in certain cases.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 66 19August 2016Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following condit ions have been met:
The results of the stud y in their entiret y have been publicly disclosed by or with the consent 
of Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at 
all study  sites for at least 2 years
The invest igator will submit to Gilead any  proposed publication or presentation along with 
the respective scientific journal or presentation forum at least 30 days before submission of 
the publication or presentation.
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees t o withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings. If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including any  clinical trial pay ments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct ac cess to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF .
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems d
etected through an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personn el for the effective conduct of any  inspection or audit.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 67 19August 20169.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. 
Should this be necessary , both parties will arrange discontinuation procedures and no tify the 
appropriate regulatory  authority (ies), IRBs, and IECs. I n terminating the study , Gilead and the 
investigator will assure that adequate consideration is given to the protection of the subjects’ 
interests.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 68 19August 201610. REFERENCES
Blanco J L, Montaner JS, Marconi VC, Santoro MM, Campos -Loza AE, Shafer RW, et al. Lower 
prevalence of drug resistance mutations at first- line virological failure to first -line 
therap y with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz 
administered on a mu ltiple tablet therap y. AIDS 2014;28 (17):2531 -9.
Callegaro A, Di Filippo E, Astuti N, Ortega PA, Rizzi M, Farina C, et al. Earl y clinical response 
and presence of viral resistant minority  variants: a proof of concept study  
[Abstract P227]. Presented at: HI V Drug Therapy Glasgow Congress 2014; 2014 
November 2 -6; Glasgow, United Kingdom. J I nt AIDS Soc 2014;17 (Suppl 
3):19759.
Centers for Disease Control and Prevention. 1993 revised classification sy stem for HIV infection 
and expanded surveillance case definition for AIDS among adolescents and 
adults. MMWR 1992;41 (RR -17):1-19.
Centers for Disease Control and Prevention. 1994 Revised Classification Sy stem for Human 
Immunodeficiency  Virus I nfection in Children Less Than 13 Years of Age. 
MMWR 1994;43 (RR -12):1-28.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31
-41.
Deval J, White KL , Miller MD, Parkin NT, Courcambeck J, Halfon P, et al. Mechanistic basis 
for reduced viral and enzy matic fitness of HIV -1 reverse transcriptase containing 
both K65R and M184V mutations. J Biol Chem 2004;279 (1):509-16.
Gibson RM, Weber J, Winner D, Miller MD, Quinones
-Mateu ME. Contribution of human 
immunodeficiency  virus ty pe 1 minorit y variants to reduced drug susceptibility  in 
patients on an integrase strand transfer inhibitor
-based therapy . PLoS ONE 
2014;9 (8):e104512.
Haubrich RH. Resistance and replication capacity  assay s: clinical utility  and interpretation. Top 
HIV Med 2004;12 (2):52 -6.
Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L , et al. Non -nucleoside 
phenoty pic h ypersusceptibility  cut-point determination from ACTG 359. HIV 
Clin Trials 2007a;8 (2):63-7.
Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, et al. The clinical 
relevan ce of non -nucleoside reverse transcriptase inhibitor hy persusceptibility : a 
prospective cohort anal ysis. AI DS 2002;16 (15):F33- F40.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 69 19August 2016Haubrich RH, Riddler SA, DiRienzo AG, Peeples L , Klingman KL, Garren KW, et al. Drug 
resistance at virological failure in a randomized, Phase III trial of NRTI -, PI-and 
NNRTI -sparing regimens for initial treatment of HIV -1 infection (ACTG 5142) 
[Abstract 57]. Presented at: XVI International HIV Drug Resistance Workshop: 
Basic Principles & Clinical I mplications; 2007 June 12-16; St. Michael, 
Barbados. Antivir Ther 2007b;12 (Suppl 1):S66.
Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, et al. Week 144 
Resistance Anal ysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF 
Versus Atazanavir+Ritonavir+Emtrici tabine/Tenofovir DF in Antiretroviral -
Naive Patients. HIV Clin Trials 2014;15 (5):218 -30.
Li JZ, Kuritzkes DR. Clinical implications of HIV -1 minority  variants. Clin I nfect Dis 2013a;56 
(11):1667-74.
Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, et al. I mpact of minority  
nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance 
genot ype after virologic failure. J I nfect Dis 2013b;207 (6):893 -7.
Marconi VC, Sunpath H, L u Z, Gordon M, Koranteng- Apeagy ei K, Hampton J, et al. Prevalence 
of HIV -1 drug resistance after failure of a first highly  active antiretroviral therap y 
regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46 (10):1589 -97.
Margot N, Liu Y, Babusis D, Miller MD, Callebaut C. Antiviral Activity of 
TenofovirAlafenamide (TAF) Against Major NRTI -Resistant Viruses: 
Improvement Over TDF/TFV Is Driven By  Higher TFV -DP L oading in Target 
Cells [Abstract 23]. Presented at: International Workshop on HIV & Hepatitis 
Virus Drug Resistance and Curative Strat egies; 2013 June 4 -8; Toronto, Canada. 
Antivir Ther 2013;18 (Suppl 1):A31.
Miller MD, Haddad M, Su C, Gibbs C, McColl DJ, Guy er B. Trends in HIV -1 reverse 
transcriptase resistance -associated mutations and antiretroviral prescription data 
from 2003- 2010. Antivir Ther 2012;17 (6):993 -9.
Miller MD, Margot N, Lu B, Zhong L, Chen S -S, Cheng A, et al. Genot ypic and phenot ypic 
predictors of the magnitude of response to tenofovir disoproxil fumarate treatment 
in antiretroviral -experienced patients. J I nfect Dis 200 4;189 (5):837 -46.
Nicot F, Saune K, Ray mond S, Jeanne N, Carcenac R, Lefebvre C, et al. Minority  resistant HIV -
1 variants and the response to first- line NNRTI therap y. J Clin Virol 2015;62:20 -
4.
Palella FJ, Fisher M, Tebas P, Gazzard B, Ruane P, L unzen JV, et al. Simplification to 
rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir -boosted 
protease inhibitor antiretroviral therap y in a randomized trial of HI V-1 RNA -
suppressed participants. AIDS 2014;28 (3):335 -44.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 70 19August 2016Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
antiretroviral agents in HIV -1-infected adults and adolescents. Department of 
Health and Human Services. Available at 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. Accessed 1 5 
August.  2016.
Poon AF, Aldous JL , Mathews WC, Kitahata M, Kahn JS, Saag MS, et al. Transmitted drug 
resistance in the CFAR network of integrated clinical sy stems cohort: prevalence 
and effects on pre -therapy  CD4 and viral load. PLoS ONE 2011;6 (6):e2118 9.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L , Powderly  WG, Klingman KL , et al. Class
-
sparing regimens for initial treatment of HIV- 1 infection. N Engl J Med 2008;358 
(20):2095-106.
Robbins BL , Greenhaw JJ, Connelly  MC, Fridland A. Metabolic pathway s for activation of the 
antiviral agent 9 -(2-phosphony lmethoxy ethyl)adenine in human ly mphoid cells. 
Antimicrob Agents Chemother 1995;39 (10):2304 -8.
Saini S, Bhalla P, Gautam H, Baveja UK, Pasha ST, Dewan R. Resistance -associated mutations 
in HIV -1 among pat ients failing first -line antiretroviral therapy . J Int Assoc 
Physicians AIDS Care (Chic) 2012;11 (3):203-9.
Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI . Morbidity  and Mortalit y 
Weekly  Report (MMWR). Revised Surveillance Case Definition f or HIV 
Infection 
-United States 2014. Centers for Disease Control and Prevention,  2014.
Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, et al. Phenoty pic 
hypersusceptibility  to non -nucleoside reverse transcriptase inhibitors in treatm ent-
experienced HIV -infected patients: impact on virological response to efavirenz -
based therap y. AIDS 2001;15 (9):1125 -32.
Wei X, L iang C, Gotte M, Wainberg MA. The M184V mutation in HI V-1 reverse transcriptase 
reduces the restoration of wild -type replica tion by  attenuated viruses. AIDS 
2002;16 (18):2391 -8.
Wei X, L iang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation in HI V-1 
reverse transcriptase on initiation of viral DNA synthesis. Virology  2003;311 
(1):202-12.
Whitcomb JM, Huang W, L imoli K, Paxinos E, Wring T, Skowron G, et al. Hy persusceptibility  
to non -nucleoside reverse transcriptase inhibitors in HIV- 1: clinical, phenoty pic 
and genot ypic correlates. AIDS 2002;16 (15):F41 -F7.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 71 19August 201611. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 6. AIDS -Defining Conditions (CDC Guidelines) {Selik et al 2014}
PJC/F ffAF 
Protocol GS-US-292-1824 Final 
Gilead Sciences , Inc. Amendment #1 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 3b Open -Labe l Pilot Study to Evaluate Switching to 
Elvitegravir /Cobicistat/Emtricitabine/f enofovi r Alafenamide (E/C/F /T AF) 
Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-] Infected Adult Subjects 
Harboring the Archived Isolated NRTI Resistance Mutation Ml 84V/M184I 
GS-US-292-1824, Amendment 1, 19 August 2016 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
PPD PD 
Medical Moni tor Signature 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
detai ls for me and my staff to conduct this study as described . I will conduct this study as 
outline d herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences , Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Numbe r 
CONFIDENTIAL Page 72 19 August 20 L6 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 73 19August 2016Appendix 2. Study Procedures Table
Study Procedure ScreeningaDay 1bEnd of Weekc
30 Day 
Follow -
up ESDDd4 8 12 16t24 36 48
Informed Consent X
Medical History X
Concomitant Medications X X X X X X X X X X X
Adverse Events X X X X X X X X X X X
Com plete Physical ExameX X X X X
Symptom -Directed Physical ExamfX X X X X
12-Lead ECG (Performed Supine) X X X
Vital Signs and Weight X X X X X X X X X X
Height X
Urinalysis and Urine Chemistry X X X X X X X X X X
Urine Storage Sample X X X X X X X X
Urine Pregnancy TestgX X X X X X X X
Serum Pregnancy TestgX
Chemistry ProfilehX X X X X X X X X X
Metabolic AssessmentsiX X X
Estimated GFRjX X X X X X X X X
Hem atology ProfilekX X X X X X X X X X
Plasma HIV- 1 RNAlX X X X X X X X X X X
CD4+ Cell Count X X X X X X X X X X
HBV and HCV SerologiesmX
Plasma Sample StoragenX X X X X X X X X
Whole Blood SamplepX
HIV-1 Genotype/PhenotypeqX X
Cystatin C TestinguX
CCI
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 74 19August 2016Study Procedure ScreeningaDay 1bEnd of Weekc
30 Day 
Follow -up ESDDd4 8 12 16t24 36 48
Questionnaires: VAS, HIVTSQs, HIVTSQc, EQ-5D, 
SF-36, and FACIT -FrX X X X X X X X X
Enrollment X
Study Drug Dispensation and Accountability X X X X X X X XsXs
a Evaluations to be completed within 42days prior to the Day 1visit.
b Subjects will be dispensed study drug on the Day 1 visit; initiation of treatment with the study drug must take place within 24 hours after the Day 1 Visit. E/C/F/TAF FDC
will be provided by the Sponsor.
c All study visits are to be scheduled relative to the Day 1visit date. Visit windows are ± 2 days of the protocol specified date thr ough Week 16, ± 6 days of the protocol 
specified date through Week 36, and all other study visits except Week 48. Week 48 visit window is± 6week s of the protocol specified visit date, and this clinical visit 
window coincides with the Week 48 statistical analysis window for HIV -1 RNA.
d Early Study Drug Discontinuation visit to occur within 72 hours of last dose of study drug. Subjects will be asked to continue attending the scheduled study visits through 
Week 48 visit even if the subject discontinues stud y drug .
e Complete physical examination every 48 week s (urogenital/anorectal exams will be performed at the discretion of the Investigator)
f Symptom -directed physical examination as needed.
g Females of childbearing potential only. Positive urine pregnanc y tests will be confirmed with a serum test.
h Chemistry profile: alkaline phosphatase, AST, ALT , total bilirubin, direct and indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, potassium andsodium . Atvisits in which metabolic assessments are to be performed, analyses of glucose will be done as part of the fasting metabolic assessments 
and not as part of the chemistry profile
.
i Metabolic Assessments: Fasting glucose and lipid panel (tot al cholesterol, HDL, direct LDL and triglycerides). If the subject has not fasted prior to the visit, the visit may 
proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.
j Estimated GFR according to the Cockcro ft-Gault formula for creatinine clearance
k CBC with differential and platelet count
l If the HIV -1 RNA value is ≥ 50 copies /mL a retest should be collected at a sc heduled or unscheduled visit, 2 -4week s after the date of the original test (except for scre ening 
and Day 1results). HIV-1 genotype/phenotype resistance testing only conducted for subjects with confirmed virologic failure with HIV-1 RNA value ≥ 50copies /mL. 
Subjects should be managed according to Figure 6-1,Management of Virologic Failure .
m H epatitis B virus surface antigen serology (HBsAg) and Hepatitis C virus (HBVAb) serology (reflex HCV RNA is performed in subj ects with positive HCVAb serology)
n Plasma sample storage for safety and virology testing
o
p Whole blood s ample collected at Screening Visit for proviral genotype analysis of archived resistance
q HIV-1 genotype/phenotype resistance testing only conducted for subjects with unconfirmed virologic rebound with HIV -1 RNA value ≥ 50copies /mL at the Week 48 and 
ESDD visit. Subjects should be managed according to Figure 6-1,Management of Virologic Failure. H IV-1 genotype/phenotype sample collection t o occu r if subjects 
HIV-1RNA lab values meet the criteria described in this section.
r EQ-5D, SF -36, and FACIT -F will be administered at Day 1, Weeks 24 and 48. VAS will be administered on Day 1, Weeks 4, 8, 12, 16, 24, 36, 48 and ESDD. HIVTSQs will 
be administ ered on Day 1. HIVTSQ c will be administered at Weeks 4, 24, 48 and ESDD.
s Drug accountability only; study drug will not be dispensed at this visit.
t At Week 16, subject will have only the following assessments completed: Review of AEs and changes in concomitant medications , blood sample collection for p lasma 
HIV-1RNA and p lasma sample storage . Study drug dispensation and accountability will be documented.
u Estimated GFR according to CKD-EPI formula for cystatin clearance will be used for Nephrotoxic ity Management per Section 7.5.4 .
CCI
E/C/F/TAF 
Protoco l GS-US-292 -1824 Final 
Gilead Sciences , Inc. Amendment #1 
Appendix 3. Management of Clinical and Laboratory Adverse Events 
Grnde 1 Grade 2 Grnde 3 Grade 4 
1 , 1, 1 • 1 • 
May continue dosing at If c.onfi.t-med and 
the discretion of the Repeat lab to confirm Repeat lab to confinn r--+ possibly or probably 
Investigator toxicity grade toxicity g..ade 1·elated to study drug, 
discontinue study 
drug dosing 
permanently and 
" " ,, follow at pel'iodic 
If confirmed and possibly and/or pl'Obably related to study drug: If confirmed and um·elated to study intervals at least 
weekly until a retur·n 
1. Withhold study drug until Grade 2 drug, dosing may continue at the to baseline or is 2. Resta11 study drug at full dose discretion of the investigator otherwise explained 
" 
If Grade 3 or 4 1·ecun·ence that is confirmed and possibly 01· If Grade 3 or 4 recunence that is considered unrela ted to study 
probably 1·elated to study drug, discontinue all study drug drug, continue all study drug at the same dose at the discretion 
dosing pei·manently of the Investigat01· 
CONFIDENTIAL Page 75 19 August 2016 
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 76 19August 2016Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL
85 to 100 g/L7.5to 8.5g/dL
75to85g/L6.5 to 7.5g/dL
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count
(ANC)
Adult and Pediatric,
≥ 7 Months#1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 77 19August 2016HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66ULN 1.66 to 2.33ULN 2.33 to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0%
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric s ubjects. Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 78 19August 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to <LLN mmo l/L 125 to130mmo l/L 121 to125mmo l/L 121mmo l/L
Hypernatremia >ULN to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN to 150 mmo l/L 150 to 154 mmo l/L 154 to 159 mmo l/L 159mmo l/L
Hypokalemia
Adult and Pediatric
1 Year3.0 to <LLN mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmo l/L 2.5 to3.0mmo l/L 2.0 to2.5mmo l/L 2.0mmo l/L
Infant <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmo l/L2.5 to3.0mEq/L
2.5 to <3.0 mmo lL2.0 to2.5mEq/L
2.0 to<2.5 mmo lL2.0 mEq/L
<2.0 mmo lL
Hyperkalemia
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmo l/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmo l/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmo l/L7.0 mEq/L
7.0mmo l/L
Infant <1 Year >ULN to 6.0 mEq/L
>ULN to 6.0 mmo l/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmo l/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmo l/L7.0 mEq/L
7.0mmo l/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmo l/L40 to55mg/dL
2.20 to3.03 mmo l/L30 to40mg/dL
1.64 to2.20 mmo l/L30mg/dL
1.64 mmo l/L
Infant,1Month 50 to 54 mg/dL
2.8 to 3.0 mmo l/L40 to 50mg/dL
2.2 to 2.8mmo l/L30 to 40mg/dL
1.7 to 2.2mmo l/L30mg/dL
1.7mmo l/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500mg/dL
6.42 to 8.91 mmo l/L 8.91 to 13.90 mmo l/L 13.90 to 27.79 mmo l/L 27.79 mmo l/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmo l/L>125 to 250 mg/dL
>6.96 to 13.90 mmo l/L>250 to 500 mg/dL
>13.90 to 27.79 mmo l/L>500 mg/dL
>27.79 mmo l/L
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 79 19August 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia
(corrected for albumin if 
appropriate* )
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmo l/L7.0 to7.8mg/dL
1.74 to1.94 mmo l/L6.1 to7.0mg/dL
1.51 to1.74 mmo l/L6.1mg/dL
1.51 mmo l/L
Pediatric ≥7days -2 Years 7.8 to 8.4 mg/dL
1.94 to 2.10 mmo l/L7.0 to <7.8 mg/dL
1.74 to <1.94 mmo lL6.1 to <7.0 mg/dL
1.51 to < 1.74 mmo lL< 6.1 mg/dL
< 1.51 mmo l/L
Infant,7Days 6.5 to 7.5mg/dL
1.61 to 1.88 mmo l/L6.0 to 6.5mg/dL
1.49 to < 1.61 mmo l/L5.5 to 6.0mg/dL
1.36 to < 1.49 mmo l/L5.5mg/dL
< 1.36 mmo l/L
Hypercalcemia (corrected for 
albumin if appropriate* )
Adult and Pediatric 7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmo l/L 2.88 to 3.13 mmo l/L 3.13 to 3.38 mmo l/L 3.38 mmo l/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10 mmo l/L12.4 to 12.9 mg/dL
> 3.10 to 3.23 mmo l/L12.9 to 13.5 mg/dL
> 3.23 to 3.38 mmo l/L13.5 mg/dL
> 3.38 mmo l/L
Hypocalcemia (ionized) 3.0mg/dL toLLN 2.5 to < 3.0 mg/dL 2.0 to2.5mg/dL 2.0mg/dL
0.74 mmo l/L toLLN 0.62 to0.74 mmo l/L 0.49 to0.62 mmo l/L 0.49 mmo l/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0mg/dL
ULN to 1.50 mmo l/L 1.50 to 1.63 mmo l/L 1.63 to 1.75 mmo l/L 1.75 mmo l/L
Hypomagnesemia 1.40 to <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to 1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmo l/L 0.43 to0.58 mmo l/L 0.28 to0.43 mmo l/L 0.28 mmo l/L
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 80 19August 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63 to LLN mmo l/L1.5 to2.0mg/dL
0.47 to0.63 mmo l/L1.0 to1.5mg/dL
0.31 to0.47 mmo l/L1.0mg/dL
0.31 mmo l/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmo l/L2.5 to 3.0mg/dL
0.80 to < 0.96 mmo l/L1.5 to 2.5mg/dL
0.47 to < 0.80 mmo l/L1.5mg/dL
<0.47 mmo l/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmo l/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmo l/L1.5 to 2.5mg/dL
0.47 to < 0.80 mmo l/L1.5mg/dL
<0.47 mmo l/L
Hyperbilirubinemia
Adult and Pediatric > 14Days 1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia
Adult and Pediatric
≥ 1year
Infant < 1 Year1.5mg/dL toLLN
87 μmol/L to LLN1.0 to1.5mg/dL
57 to87 μmol/L0.5 to1.0mg/dL
27 to57 μmol/L0.5mg/dL
27 μmol/L
N/A 1.0mg/dl to <LLN -
57 μm ol to <LLN0.5 to1.0mg/dL
27 to57 μmol/L0.5mg/dL
27 μmol/L
Creatinine ** 1.50to 2.00mg/dL
133to 177μmol/L2.00to 3.00mg/dL
177to 26 5 μmol/L3.00 to 6. 00mg/dL
265to 530 μmol/L6.00mg/dL
530 μ mol/L
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 81 19August 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Bicarbonate
Adult and Pediatric
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmo l/L toLLN 11.0 to16.0 mmo l/L 8.0 to11.0 mmo l/L 8.0mmo l/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmo l/L to <LLN 8.0 to11.0 mmo l/L 8.0mmo l/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmo l/L750 to 1200 mg/dL
8.47–13.55 mmo l/L1200 mg/dL
13.55 mmo l/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmo l/L >4.15 to 4.92 mmo l/L >4.92 mmo l/L
LDL (Fasting)
Pediatric >2 to <18 year s110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmo l/L >3.37 to 4.92 mmo l/L >4.92 mmo l/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300mg/dL NA
5.16 to 6.19 mmo l/L 6.19 to 7.77 mmo l/L 7.77 mmo l/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmo l/L199 to 300 mg/dL
5.15 to 7.77 mmo l/L300mg/dL
7.77 mmo l/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calc ium should be cor rected for albumin if albumin is < 4.0 g/dL.
** An overlap between the Grade 1 scale and the Lab’ snormal range for creatinine may result for Male subjects > 70 yrs. Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 82 19August 2016ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 year s
≥ 16 year s- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 83 19August 2016URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative)
See Note below
Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric
10 Years200 to999mg/24h >999 to1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric
3 Mo to < 10Years201 to499mg/m2/24h >499 to799mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Note s:
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxici ty grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two 
grades for the AE.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 84 19August 2016CARDIOV ASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac A rrhythmia (general)
(By ECG or physical exam)Asymptomatic AND 
Nointervention indicatedAsymptomatic AND 
Non-urgent medical 
intervention indicatedSymptomatic, 
non-life-threatening AND 
Non-urgent medical
intervention indicatedLife-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/I nfarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemiaUnstable angina OR Acute 
myocardial infarction
Hem orrhage
(significant acute blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicatedLife-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated
(for children 10cc/kg) 
indicated
Hypertension (wit h repeat 
testing at same visit)140– 159mmH g systolic
OR
90–99 mmHg diastolic159–179 mmHg systolic
OR
99–109 mmHg diastolic179mmHg systolic
OR
109mmHg diastolicLife-threatening 
consequences
(e.g., malignant 
hypertension) OR 
Hospitalization (other than 
ER visit) indicated
Pediatric 17Years 
(withrepeat testing at same 
visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted for 
age, height, and gender 
(systolic and/or diastolic)Life-threatening 
consequences
(e.g., malignant 
hypertension) OR 
Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 85 19August 2016CARDIOV ASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Pericardial E ffusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusi on requiring no 
interventionEffusion with 
non-life-threatening 
physiologic consequences 
OR Effusion with nonurgent 
intervention indicatedLife-threatening 
consequences 
(e.g.,tamponade) OR Urgent 
intervention indicated
Prolonged PR Interval PR interval
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV block 
OR Ventricular pause 
3.0secCom plete AV block
Pediatric 16 Y ears 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade 
de pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 secAsymptomatic, QTc interval 
0.465 to 0.479 secAsymptomatic, QTc interval 
0.480 secLife-threatening 
consequences, eg, Torsade 
de pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/E mbolism NA Deep vein thrombosis AND 
No intervention indicated 
(e.g., anticoagulation, lysis 
filter, invasive procedure)Deep vein thrombosis AND 
Intervention indicated ( e.g., 
anticoagulation, lysis filter, 
invasive procedure)Embolic event 
(e.g.,pulmonary embolism, 
life-threatening thrombus)
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousnessPresent with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 86 19August 2016RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced 
to 70% to 80%FEV1 or peak flow  50% to 
69%FEV1 or peak flow  25% to 
49%Cyanosis OR FEV1 or peak 
flow 25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activitiesDyspnea on exertion causing 
greater than minimal 
interference with usual social 
& functional activitiesDyspnea at rest causing 
inability to perform usual 
social & functional activitiesRespiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate 
for ageNasal flaring OR Intercostal 
retractions OR Pulse 
oximetry 90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis 
OR Medical intervention 
indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in 
affected eye(s)
Visual Changes (from baseline) Visual changes causing no or 
minimal interference with
usual social & functional 
activitiesVisual changes causing 
greater than minimal 
interference with usual social 
& functional activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in 
affected eye( s)
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 87 19August 2016SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by study 
participant or caregiver
(for disabled adults)Thinning or patchy hair loss 
detectable by health care 
providerCom plete hair loss NA
Cutaneous Reaction – Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesionsDiffuse macular, 
maculopapular, or 
morbilliform rash with 
vesicles or limited number of 
bullae OR Superficial 
ulcerations of mucous 
membrane limited to one siteExtensive o r generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two or 
more distinct mucosal sites 
OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis
(itching –no skin lesions)
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activitiesNA
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 88 19August 2016GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetit e without 
decreased oral intakeLoss of appetite associated 
with decreased oral intake 
without significant weight 
lossLoss of appetite associated 
with significant weight lossLife-threatening 
consequences OR 
Aggressive intervention 
indicated [ eg, tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND 
Intervention indicated ( e.g., 
diuretics or therapeutic 
paracentesis)Symptomatic despite 
interventionLife-threatening 
consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening 
consequences
(e.g., sepsis or perforation)
Constipation NA Persistent constipation 
requiring regular use of 
dietary modifications, 
laxatives, or enemasObstipation with manual 
evacuation indicatedLife-threatening 
consequences 
(e.g.,obstruction)
Diarrhea
Adult and Pediatric 1 Year Transient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of 
unformed to watery stools 
OR Increase of 4 –6 stools 
over baseline per 24 hrs.Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening 
consequences 
(e.g.,hypotensive shock)
Pediatric 1 Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without 
medical intervention 
indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention 
indicatedLife-threatening reduction in 
oral intake
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 89 19August 2016GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/S tomatitis
(clinical exam)
See also Pr octitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerationsConfluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal 
bleeding OR Life -threatening 
consequ ences
(e.g., aspiration, choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 
24-48 hoursPersistent nausea resulting in 
minimal oral intake for 
48hours OR Aggressive 
rehydration indicated 
(e.g.,IVfluids)Life-threatening 
consequences 
(e.g.,hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening 
consequences 
(e.g.,sepsis, circulatory 
failure, hemorrhage)
Proctitis
(functional -symptomatic)
Also see Mucositis/ Stomatitis 
for Clinical E xamRectal discomfor t AND 
Nointervention indicatedSymptoms causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Medical intervention 
indicatedSymptoms causing inability 
to perform usual social/
functional activities OR 
Operative intervention 
indicatedLife-threatening 
consequences 
(e.g.,perforation)
Vom iting Transient or intermittent 
vomiting with no or minimal 
interference with oral intakeFrequent episodes of 
vomiting with no or mild 
dehydrationPersistent vomiting resulting 
in orthostatic hypotension 
OR Aggressive rehydration 
indicatedLife-threatening 
consequences 
(e.g.,hypotensive shock)
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 90 19August 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in 
Personality -Behavior or in 
Mood(eg,agitation, anxiety, 
depression, mania, psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activitiesAlteration causing greater 
than minimal interference 
with usual social & 
functional activitiesAlteration causin g inability 
to perform usual social & 
functional activitiesBehavior potentially harmful 
to self or others 
(e.g.,suicidal/homicidal 
ideation or attempt, acute 
psychosis) OR Causing 
inability to perform basic 
self-care functions
Altered Mental Status
For Dem entia, see 
Cognitive and Behavioral/
Attentional D isturbance 
(including dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usu al social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, 
OR coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no or 
minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional ac tivitiesDisabling ataxia causing 
inability to perform basic 
self-care functions
Cognitive a nd Behavioral/
Attentional Disturbance 
(including dementia and 
Attention Deficit Disorder)Disability causing no or 
minimal interference with 
usual social & functi onal 
activities OR Specialized 
resources not indicatedDisability causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Specialized resources on 
part-time basis indicatedDisability causing inability 
to perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability 
to perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 91 19August 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the settingModerate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the settingSevere developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the settingDevelopmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & 
functional activitiesSymptoms causing inability 
to perform usual social & 
functional activitiesSymptoms causing inability 
to perform basic self -care 
functions OR Hospitalization 
indicated (other than ER 
visit) OR Headache with 
significant impairment of 
alertness or other neurologic 
function
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic 
self-care functions
Neuromuscular Weakness
(including myopathy & 
neuropathy)Asymptomatic with 
decreased strength o n exam 
OR Minimal muscle 
weak -ness causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activitiesDisabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respiratory muscle 
weakness impairing 
ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social & 
functional activitiesSensory alteration or 
paresthesia causing greater 
than minimal interference 
with usual social & 
functional activitiesSenso ry alteration or 
paresthesia causing inability 
to perform usual social & 
functional activitiesDisabling sensory alteration 
or paresthesia causing 
inability to perform basic 
self-care functions
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 92 19August 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive 
(e.g.,status epilepticus), or 
difficult to control 
(e.g.,refractory epilepsy)
Seizure: (pre- existing)
For Worsening of Existing 
Epilepsy the Grades Should Be 
Based on an Increase from 
Previous Level of Control to 
Any of These LevelsNA Increased frequency of 
pre-existing seizures 
(non-repetitive) without 
change in seizure character 
OR infrequent breakthrough 
seizures while on stable 
meds in a previously 
controlled seizure disorderChange in seizure character 
from b aseline either in 
duration or quality 
(e.g.,severity or focality)Seizures of any kind that are 
prolonged, repetitive 
(e.g.,status epilepticus), or 
difficult to control 
(e.g.,refractory epilepsy)
Seizure –
Pediatric 18 YearsSeizure, generalized onset 
with or without second ary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without se condary  
generalization, lasting 
5-20minutes with
< 24 hours post ictal stateSeizure, generalized onset 
with or without se condary  
generalization, lasting
>20minutesSeizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated with a 
procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activitiesVertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic 
self-care functions
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 93 19August 2016MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater 
than minimal interference 
with usual social & 
functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic 
self-care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing greater than minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform ba sic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0BMD t -score or z- score
–2.5Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening 
consequences
Pediatric 21Years BMD z -score
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening 
consequences
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater 
than minimal interference 
with usual social & 
functional activitiesMuscle pain causing inability 
to perform usual social & 
functional activitiesDisabling muscle pain 
causing inability to perform 
basic self -care functions
Osteonecrosis NA Asymptomatic with 
radiographic findings AND 
No operative intervention 
indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings 
causing inability to perform 
basic self -care functions
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 94 19August 2016SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
ReactionLocalized urticaria (wheals) 
with no medical intervention 
indicatedLocalized urticaria with 
medical intervention 
indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralize d urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomat ic mild 
bronchospasmAcute anaphylaxis OR 
Life-threatening 
bronchospasm OR laryngeal 
edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & 
functional activitiesSymptoms causing inability 
to perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & 
functional activitiesSymptoms causing inability 
to perform usual social & 
functional activitiesIncapacitating 
fatigue/ malaise symptoms 
causing inability to perform 
basic self -care functions
Fever (nonaxillary) 37.7C to 38.6C
99.8Fto 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C
104.9F
Pain- Indicate Body  Site
See also Injection Site P ain, 
Headache, Arthralgia, and 
MyalgiaPain causing no or minimal 
interference with usual social 
& functional activitiesPain causing greater than 
minimal interference with 
usual social & functional 
activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization (other than 
ER visit) indicated
Unintentional Weight L oss NA 5% to 9% loss in body 
weight from baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR 
Aggressive intervention 
indicated [ eg, tube feeding or 
total parenteral nutrition]
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 95 19August 2016INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site P ain
(pain w ithout touching)
Or Tenderness
(pain when area is touched)Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use 
of limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing 
inability to perform basic 
self-care function OR 
Hospitalization (other than 
ER visit) indicated for 
management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm 
(or2581cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (invo lving dermis 
and deeper tissue)
Pediatric 15Years Erythema OR Induration OR 
Edema present but 2.5cm 
diam eterErythema OR Induration OR 
Edema > 2.5cm diam eter 
but < 50% surfac e area of the 
extremity segment
(e.g., upper arm/thigh)Erythema OR Induration OR 
Edema involving 50% 
surface area of the extremity 
segment ( e.g., upper 
arm/thigh) OR Ulceration 
OR Secondary infection OR 
Phlebitis OR Sterile abscess 
OR DrainageNecrosis (involving dermis 
and deeper tissue)
Pruritis Associated with 
Injection
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 48h 
treatmentItching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h 
treatmentGeneralized itching causing 
inability to perform usual 
social & functional activitiesNA
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 96 19August 2016ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy ( e.g., back of 
neck, breasts, abdomen)Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)Detectable on physical exam 
by health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need to 
initiate medication OR 
Modification of current meds 
to regain glucose controlNew  onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite 
treatment modificationLife-threatening 
consequences 
(e.g.,ketoacidosis, 
hyperosmolar non -ketotic 
coma)
Gynecomastia Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)Detectable on physical exam 
by health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despite 
treatment modificationLife-threatening 
consequences
(e.g., thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater 
than mi nimal interference 
with usual social & 
functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despite 
treatment modificationLife-threatening 
consequences
(e.g., myxedema coma)
Lipoatrophy ( e.g., fat loss from 
the face, extremities, buttocks)Detectable by stud y 
participant or caregiver 
(foryoung children and 
disabled adults)Detectable on physical exam 
by health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 97 19August 2016GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding (IMB) Spotting observed by 
participant OR Minimal 
blood observed during 
clinical or colposcopic examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding 
greater in duration or amount 
than usual menstrual cycleHem orrhage with 
life-threatening hypotension 
OR Operative intervention 
indicated
Urinary T ract obstruction 
(e.g.,stone)NA Signs or symptoms of 
urinary tract obstruction 
without hydronephrosis or 
renal dysfunctionSigns or symptoms of 
urinary tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing 
life-threatening 
consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection
(any other than HIV infection)Localized, no systemic 
antiμ bial treatment indicated 
AND Symptoms causing no 
or minimal interference with 
usual social & functional 
activitiesSystemic anti μbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic anti μbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than 
simple incision and drai nage) 
indicatedLife-threatening 
consequences
(e.g., septic shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, e tc.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 98 19August 2016Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Con traceptive Requirements
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, 
unless 
permanentl y sterile or with medical ly documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 month s wit hout an alternative cause. 
Inaddition, women of any  age with amenorrhea of > 12 month s may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male born subject is considered of fertile after the initiation of
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requirements for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
The data of stud y drugs on pregnant wome n is limited or not available. There is no suspicion of 
human teratogenicit y based on class e ffects or genotoxic potential. Relevant non clinical 
reproductive toxicity  studies for human pregnancy  do not indicate a strong suspicion of human 
teratogenicit y/fetotoxicity . Data from clinical pharmacokinetic interaction studies of study  drug 
have demonstrated that there is no reduction in the clinical efficacy  of hormonal contraception or 
that the effect on hormonal contraception is insignificant. Please refer to the latest version of the 
investigator’s brochure for additional information.
b)Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. They  must also not rely  on hormone -containing contraceptives as a form 
of birth control during the study . They  must have a negative serum pregnancy  test at Screening 
prior to study  enrollment . A serum 
pregnancy  test will be performed at all study  visits and the 
end of relevant s ystem exposure. In the event of a delay ed menstrual period (over one month
between menstruations), a serum pregnancy  test must be pe rformed to rule out pregnancy . 
This iseven true for women of childbearing potential with infrequent or irr egular periods. 
Female subjects must agree to one of the following from Screening until 30 days following the 
end of relevant s ystemic exposure.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 99 19August 2016Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contracep tion only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below:
Intrauterine device (IUD) with a failure rate of < 1% per year
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 month s after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 month s after procedure)
Or
Consistent and correct use of one hormonal method and one barrier method :
Barrier methods
oDiaphragm with spermicide
oCervical cap with spermicide
oMale condom (with or without spermicide)
Hormonal methods (the hormonal contraceptive should contain at least 30 mcg of 
ethiny lestradiol)
oIntrauterine hormone -releasing s ystem (IUS) with a failure rate of < 1%peryear
oOral contraceptives (either combined or progesterone only )
oInjectable progesterone
oImplants of levonorgestrel
oTransdermal contraceptive patch
oContraceptive vagina l ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 days after the end of relevant sy stemic exposure.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 100 19August 20163) Contraception Requirements for Male Subjects
During the study , male subjects with female partners of childbearing potential should use 
condoms when engaging in intercourse of reproductive potential.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, ovulation,
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenor rhea method (LAM). Female condom and male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects wil l be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30days of last study  drug dose. S ubjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Instructions for 
reporting pregnancy , and pregnancy  outcome are outl ined in Section 7.6.2.1.
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 101 19August 2016Appendix 6. AIDS -Defining Conditions (CDC Guidelines) {Selik et al 2014 }
Bacterial infections, multiple or recurrent*
Candidiasis of bronchi, trachea, or lungs
Candidiasis of esophagus
Cervical cancer, invasive†
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (> 1month 's duration)
Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age > 1month
Cytomegalovirus retinitis (with loss of vision)
Encephalopath y attributed to HIV§
Herpes simplex: chronic ulcers (> 1month 's duration) or bronchitis, pneumonitis, or 
esophagitis (onset at age > 1month )
Histoplasmosis, disseminated or extrapulmonar y
Isosporiasis, chronic intestinal (> 1 month 's duration)
Kaposi sarcoma
Lym phoma, Burkitt (or equivalent term)
Lym phoma, immunoblastic (or equivalent term)
Lym phoma, primary , of brain
Mycobacterium avium complex or Mycobacterium kansasii , disseminated or extrapulmonary
Mycobacterium tuberculosis of any  site, pulmonary†, disseminated, or extrapulmonary
Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
Pneumocystis jirovecii (previously  known as " Pneumocystis carinii ") pneumonia
Pneumonia, recurrent†
E/C/F/TAF
Protocol GS -US-292-1824 Final
Gilead Sciences, Inc. Amendment #1
CONFIDENTIAL Page 102 19August 2016Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain, onset at age > 1month
Wasting sy ndrome attributed to HIV§
*Only among children aged < 6years
†Only among adults, adolescents, and children aged ≥ 6years
§Suggested diagnostic criteria for these illnesses, which might be particularly important for HIV encephalopathy 
and HIV w asting syndrome, are described in the following references {Centers for Disease Control and 
Prevention 1994 }, {Centers for Disease Control and Prevention 1992 } .